Vitamin D cancer studies

7/23/2019 Vitamin D cancer studies

1/50

1 | P a g e

Highly Cited and Recent Papers on

UVB and/or Vitamin D and Cancer(826 Papers)

William B. Grant, Ph.D.Sunlight, Nutrition, and Health Research Center (SUNARC)

P.O. Box 641603San Francisco, CA 94164, USA

www.sunarc.org, [email protected]

Note: Abstracts are generally available through www.pubmed.gov. Also, an estimate of the number of citations can beobtained through Google Scholar: http://scholar.google.com/ using the search terms such as: author:A author:Einstein.The number of citations from Google Scholar (GS) will be somewhat different from those for the Institute of ScientificInformation (ISI) (http://www.isinet.com/) since ISI looks at citations only from journal articles while GS includes a few fromother sources. Unfortunately, ISI is only available through subscription, such as at a library or institution. (The number ofcitations were updated on Sept. 10, 2008 for the more highly cited papers dating back to 2002 and Nov, 2007 dating backto 1998.)

From http://sciencewatch.com/about/met/thres-highlyctd/, it appears as if Im using a criterion of 1/3 the threshold for thetop 1% of cited papers per year for clinical medicine in the 1990s. Therefore, this fraction should also be appliedthereafter. The thresholds for the top 1 percentile through June 30, 2008 (posted September 1) from that URL are:

Year 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008

Threshold 190 183 176 165 156 139 126 107 84 62 36 14 3

I consider 1/3 of these values to be the threshold for highly cited papers on vitamin D and cancer.

2008112 papers (17 epub) (at this rate, 139 in year)

Abbas S, Linseisen J, Slanger T, Kropp S, Mutschelknauss E, Flesch-Janys D, Chang-Claude J. Serum 25-hydroxyvitamin D and risk of postmenopausal breast cancer - results of a large case-control study. Carcinogenesis. 2008Jan;29(1):93-9. (5 ISI)


2/50

2 | P a g e

Abbas S, Nieters A, Linseisen J, Slanger T, Kropp S, Mutschelknauss EJ, Flesch-Janys D, Chang-Claude J. Vitamin Dreceptor gene polymorphisms and haplotypes and postmenopausal breast cancer risk. Breast Cancer Res. 2008 Apr17;10(2):R31

Abbas S, Linseisen J, Slanger T, Kropp S, Mutschelknauss EJ, Flesch-Janys D, Chang-Claude J. The gc2 allele of thevitamin d binding protein is associated with a decreased postmenopausal breast cancer risk, independent of the vitamin dstatus. Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6):1339-43.

Ahn J, Peters U, Albanes D, Purdue MP, Abnet CC, Chatterjee N, Horst RL, Hollis BW, Huang WY, Shikany JM, HayesRB; For the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Project Team. Serum Vitamin DConcentration and Prostate Cancer Risk: A Nested Case-Control Study. J Natl Cancer Inst. 2008;11:796-804.

Atkinson SA. Vitamin D status and bone biomarkers in childhood cancer. Pediatr Blood Cancer. 2008 Feb;50(2Suppl):479-82; discussion 486. Review.

Badros A, Goloubeva O, Terpos E, Milliron T, Baer MR, Streeten E. Prevalence and significance of vitamin D deficiency inmultiple myeloma patients. Br J Haematol. 2008 May 15. [Epub ahead of print]

Bao BY, Ting HJ, Hsu JW, Lee YF. Protective role of 1 alpha, 25-dihydroxyvitamin D3 against oxidative stress innonmalignant human prostate epithelial cells. Int J Cancer. 2008 Jun 15;122(12):2699-706.

Baquet CR, Mishra SI, Commiskey P, Ellison GL, DeShields M. Breast cancer epidemiology in blacks and whites:disparities in incidence, mortality, survival rates and histology. J Natl Med Assoc. 2008 May;100(5):480-8.

Barreto SG, Ramadwar MR, Shukla PJ, Shrikhande SV. Vitamin D3 in operable periampullary and pancreatic cancer:perioperative outcomes in a pilot study assessing safety. Pancreas. 2008 Apr;36(3):315-7.

Beres S. Vitamin D: Cancer Prevention's Sunny Future? J Natl Cancer Inst. 2008;100: 292-297.

Berwick M, Lachiewicz A, Pestak C, Thomas N. Solar UV exposure and mortality from skin tumors. Adv Exp Med Biol.2008;624:117-24.

Bikle DD. Vitamin D Receptor, UVR, and Skin Cancer: A Potential Protective Mechanism. J Invest Dermatol. 2008Oct;128(10):2357-2361.

Blackmore KM, Lesosky M, Barnett H, Raboud JM, Vieth R, Knight JA. Vitamin D From Dietary Intake and Sunlight

Exposure and the Risk of Hormone-Receptor-Defined Breast Cancer. Am J Epidemiol. 2008 Aug 27. [Epub ahead of print]

Boffetta P, Hel OV, Kricker A, Nieters A, Sanjos SD, Maynadi M, Cocco PL, Staines A, Becker N, Font R, Mannetje AT,Goumas C, Brennan P. Exposure to ultraviolet radiation and risk of malignant lymphoma and multiple myeloma--amulticentre European case-control study. Int J Epidemiol. 2008 May 29. [Epub ahead of print]

Cannell J, Hollis B, Zasloff M, Heaney R. Diagnosis and treatment of vitamin D deficiency. Expert Opin Pharmacother.2008 Jan;9(1):107-118.

Cantor I. Shedding Light on Vitamin D and Integrative Oncology. Integr Cancer Ther. 2008 Jun;7(2):81-9.

Carless MA, Kraska T, Lintell N, Neale RE, Green AC, Griffiths LR. Polymorphisms of the VDR gene are associated withpresence of solar keratoses on the skin. Br J Dermatol. 2008 Jul 19. [Epub ahead of print]

Chen TC. 25-Hydroxyvitamin D-1 alpha-hydroxylase (CYP27B1) is a new class of tumor suppressor in the prostate.Anticancer Res. 2008 Jul-Aug;28(4A):2015-7.

Cherniack EP, Florez H, Roos BA, Troen BR, Levis S. Hypovitaminosis D in the elderly: from bone to brain. J Nutr HealthAging. 2008 Jun-Jul;12(6):366-73.

Cheung E, Wadhera P, Dorff T, Pinski J. Diet and prostate cancer risk reduction. Expert Rev Anticancer Ther. 2008Jan;8(1):43-50.


3/50

3 | P a g e

Clendenen TV, Arslan AA, Koenig KL, Enquist K, Wirgin I, Gren S, Lukanova A, Sjodin H, Zeleniuch-Jacquotte A, ShoreRE, Hallmans G, Toniolo P, Lundin E. Vitamin D receptor polymorphisms and risk of epithelial ovarian cancer. CancerLett. 2008 Feb 18;260(1-2):209-215.

Colli JL, Grant WB. Solar ultraviolet B radiation compared with prostate cancer incidence and mortality rates in UnitedStates. Urology. 2008 Mar;71(3):531-5.

Davis CD. Vitamin D and cancer: current dilemmas and future research needs. Am J Clin Nutr. 2008 Aug;88(2):565S-569S.

Ding EL, Mehta S, Fawzi WW, Giovannucci EL. Interaction of estrogen therapy with calcium and vitamin Dsupplementation on colorectal cancer risk: reanalysis of Women's Health Initiative randomized trial. Int J Cancer. 2008

Apr 15;122(8):1690-4.

Dixon KM, Mason RS. Vitamin D. Int J Biochem Cell Biol. 2008 Aug 3. [Epub ahead of print]

Egan KM, Signorello LB, Munro HM, Hargreaves MK, Hollis BW, Blot WJ. Vitamin D insufficiency among African-Americans in the southeastern United States: implications for cancer disparities (United States). Cancer Causes Control.2008 Jun;19(5):527-35.

Evans S, Metcalfe C, Ibrahim F, Persad R, Ben-Shlomo Y. Investigating Black-White differences in prostate cancerprognosis: A systematic review and meta-analysis. Int J Cancer. 2008 May 1;123(2):430-435.

Everett PC. The prevalence of vitamin D deficiency and insufficiency in a hematology-oncology clinic. Clin J Oncol Nurs.2008 Feb;12(1):33-5.

Fleet JC. Molecular actions of vitamin D contributing to cancer prevention. Mol Aspects Med. 2008 Aug 8. [Epub ahead ofprint]

Freedman DM. Commentary: The complexities of minimizing risks due to UV exposures. Int J Epidemiol. 2008;37:667-8.

Freedman DM, Chang SC, Falk RT, Purdue MP, Huang WY, McCarty CA, Hollis BW, Graubard BI, Berg CD, Ziegler RG.Serum Levels of Vitamin D Metabolites and Breast Cancer Risk in the Prostate, Lung, Colorectal, and Ovarian CancerScreening Trial. Cancer Epidemiol Biomarkers Prev. 2008 Apr;17(4):889-94.

Freedman DM, Looker AC, Chang SC, Graubard BI. Response: Re: Prospective Study of Vitamin D and Cancer Mortality

in the United States. Journal of the National Cancer Institute June 4 2008;100:827-8.

Ganry O, Laptre-Ledoux B, Fardellone P, Dubreuil A. Bone mass density, subsequent risk of colon cancer and survivalin postmenopausal women. Eur J Epidemiol. 2008;23(7):467-73.

Gapska P, Scott RJ, Serrano-Fernandez P, Huzarski T, Byrski T, Kadny J, Gronwald J, Grski B, Cybulski C, Lubinski J,Dbniak T. Vitamin D receptor variants and breast cancer risk in the Polish population. Breast Cancer Res Treat. 2008Jun 29. [Epub ahead of print]

Garland CF, Gorham ED, Baggerly CA, Garland FC. Re: Prospective Study of Vitamin D and Cancer Mortality in theUnited States. J Natl Cancer Inst. June 4 2008;100:826-7.

Giovannucci E. Vitamin D status and cancer incidence and mortality. Adv Exp Med Biol. 2008;624:31-42.

Giovannucci E. Vitamin D and Cancer Incidence in the Harvard Cohorts. Ann Epidemiol. 2008 Feb 19; [Epub ahead ofprint]

Gissel T, Rejnmark L, Mosekilde L, Vestergaard P. Intake of vitamin D and risk of breast cancer-A meta-analysis. JSteroid Biochem Mol Biol. 2008 Sep;111(3-5):195-9.

Goodwin WJ, Thomas GR, Parker DF, Joseph D, Levis S, Franzmann E, Anello C, Hu JJ. Unequal burden of head andneck cancer in the United States. Head Neck. 2008 Mar;30(3):358-71.


4/50

4 | P a g e

Grandin L, Orsi L, Troussard X, Monnereau A, Berthou C, Fenaux P, Marit G, Soubeyran P, Huguet F, Milpied N,Leporrier M, Hemon D, Clavel J. UV radiation exposure, skin type and lymphoid malignancies: results of a French case-control study. Cancer Causes Control. 2008;19 (3):305-315.

Grant WB. The effect of solar UVB doses and vitamin D production, skin cancer action spectra, and smoking in explaininglinks between skin cancers and solid tumours. Eur J Cancer. 2008;44:12-15.

Grant WB. Solar ultraviolet irradiance and cancer incidence and mortality. Adv Exp Med Biol. 2008;624:16-30.

Grant WB. Hypothesis-Ultraviolet-B irradiance and vitamin D reduce the risk of viral infections and thus their sequelae,including autoimmune diseases and some cancers. Photochem Photobiol. 2008;84:356-65. (3 ISI)

Grant WB. Response to comments by Norval and Woods to my hypothesis regarding vitamin D, viral infections and theirsequelae. Photochem Photobiol. 2008 May-Jun;84(3):806-8.

Grant WB. An ecological study of cancer mortality rates including indices for dietary iron and zinc. Anticancer Res. 2008May-Jun;28(3B):1955-63.

Grant WB. Re: Prospective Study of Vitamin D and Cancer Mortality in the United States. JNCI June 4 2008;100:826.

Grant WB. Ecologic approach is a powerful tool for cancer research. Eur J Cancer Prev. 2008 Aug;17(4):384.

Grant WB. Vitamin D, periodontal disease, tooth loss, and cancer risk. Lancet Oncology. 2008 July;9(7):612-613.

Grant WB. Commentary: Ecologic studies in identifying dietary risk factors for coronary heart disease and cancer. Int JEpidemiol. 2008 Aug 24. [Epub ahead of print]

Grant WB. Differences in vitamin D status may explain black-white differences in breast cancer survival rates. J Natl MedAssoc. 2008 Sept;100(9):1040.

Greenspan SL. Approach to the prostate cancer patient with bone disease. J Clin Endocrinol Metab. 2008 Jan;93(1):2-7.

Grimsrud TK, Andersen A. Protective effect from solar exposure, risk of an ecological fallacy. Eur J Cancer.2008;44(1):16-18.

Heaney RP. Vitamin D and calcium interactions: functional outcomes. Am J Clin Nutr. 2008 Aug;88(2):541S-544S.

Holick MF. Sunlight, UV-radiation, vitamin D and skin cancer: how much sunlight do we need? Adv Exp Med Biol.2008;624:1-15.

Hu DN, McCormick SA, Yu GP. Latitude and uveal melanoma. Ophthalmology. 2008 Apr;115(4):757; author reply 757-9.

Hubner RA, Muir KR, Liu JF, Logan RF, Grainge MJ, Houlston RS; Members of UKCAP Consortium. Dairy products,polymorphisms in the vitamin D receptor gene and colorectal adenoma recurrence. Int J Cancer. 2008 Aug 1;123(3):586-93.

Huh SY, Gordon CM. Vitamin D deficiency in children and adolescents: Epidemiology, impact and treatment. Rev EndocrMetab Disord. 2008 Jun;9(2):161-170.

Huncharek M, Muscat J, Kupelnick B. Dairy products, dietary calcium and vitamin d intake as risk factors for prostatecancer: a meta-analysis of 26,769 cases from 45 observational studies. Nutr Cancer. 2008 Jul-Aug;60(4):421-41.

Ingraham BA, Bragdon B, Nohe A. Molecular basis of the potential of vitamin D to prevent cancer. Curr Med Res Opin.2008;24:139-49.

Karami S, Brennan P, Hung RJ, Boffetta P, Toro J, Wilson RT, Zaridze D, Navratilova M, Chatterjee N, Mates D, JanoutV, Kollarova H, Bencko V, Szeszenia-Dabrowska N, Holcatova I, Moukeria A, Welch R, Chanock S, Rothman N, ChowWH, Moore LE. Vitamin d receptor polymorphisms and renal cancer risk in central and eastern europe. J Toxicol EnvironHealth A. 2008 Jan;71(6):367-72.


5/50

5 | P a g e

Khazai N, Judd SE, Tangpricha V. Calcium and vitamin D: skeletal and extraskeletal health. Curr Rheumatol Rep. 2008Apr;10(2):110-7.

Kricker A, Armstrong BK, Hughes AM, Goumas C, Smedby KE, Zheng T, Spinelli JJ, De Sanjose S, Hartge P, Melbye M,Willett EV, Becker N, Chiu BC, Cerhan JR, Maynadie M, Staines A, Cocco P, Boffeta P; for the Interlymph Consortium.Personal sun exposure and risk of non Hodgkin lymphoma: A pooled analysis from the Interlymph Consortium. Int JCancer. 2008 Jan 1;122(1):144-54.

Kristal AR, Arnold KB, Schenk JM, Neuhouser ML, Goodman P, Penson DF, Thompson IM. Dietary patterns, supplementuse, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am JEpidemiol. 2008 Apr 15;167(8):925-34.

Kurihara N, Fan K, Thaler HT, Yang K, Lipkin M. Effect of a Western-Style Diet Fortified with Increased Calcium andVitamin D on Mammary Gland of C57Bl/6 Mice. J Med Food. 2008 Jun;11(2):201-206.

Larriba MJ, Valle N, Alvarez S, Muoz A. Vitamin D3 and colorectal cancer. Adv Exp Med Biol. 2008;617:271-80.

Larsson D, Hagberg M, Malek N, Kjellberg C, Senneberg E, Tahmasebifar N, Johansson V. Membrane initiated signalingby 1,25alpha-dihydroxyvitamin D3 in LNCaP prostate cancer cells. Adv Exp Med Biol. 2008;617:573-9.

Lu L, Qiu J, Liu S, Luo W. Vitamin D3 analogue EB1089 inhibits the proliferation of human laryngeal squamous carcinomacells via p57. Mol Cancer Ther. 2008 May;7(5):1268-74.

Lucas RM, McMichael AJ, Armstrong BK, Smith WT. Estimating the global disease burden due to ultraviolet radiationexposure. Int. J. Epidemiol. 2008 37: 654-667.

McCullough ML, Bandera EV, Moore DF, Kushi LH. Vitamin D and calcium intake in relation to risk of endometrial cancer:A systematic review of the literature. Prev Med. Prev Med. 2008 Apr;46(4):298-302.

Menezes RJ, Cheney RT, Husain A, Tretiakova M, Loewen G, Johnson CS, Jayaprakash V, Moysich KB, Salgia R, ReidME. Vitamin d receptor expression in normal, premalignant, and malignant human lung tissue. Cancer EpidemiolBiomarkers Prev. 2008 May;17(5):1104-10.

Moan J, Porojnicu AC, Dahlback A, Setlow RB. Addressing the health benefits and risks, involving vitamin D or skincancer, of increased sun exposure. Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):668-73. (7 ISI)

Mohr SB, Garland CF, Gorham ED, Grant WB, Garland FC. Could ultraviolet B irradiance and vitamin D be associatedwith lower incidence rates of lung cancer? J Epidemiol Community Health. 2008 Jan;62(1):69-74.

Mohr SB, Garland CF, Gorham ED, Grant WB, Garland FC. Relationship between low ultraviolet B irradiance and higherbreast cancer risk in 107 countries. Breast J. 2008;141:255-60.

Mucci LA, Spiegelman D. Vitamin D and prostate cancer riskA less sunny outlook? JNCI. June 2008;100 (11):759-61.

Myrthue A, Rademacher BL, Pittsenbarger J, Kutyba-Brooks B, Gantner M, Qian DZ, Beer TM. The Iroquois HomeoboxGene 5 Is Regulated by 1,25-Dihydroxyvitamin D3 in Human Prostate Cancer and Regulates Apoptosis and the CellCycle in LNCaP Prostate Cancer Cells. Clin Cancer Res. 2008 Jun 1;14(11):3562-3570.

Neuhouser ML, Sorensen B, Hollis BW, Ambs A, Ulrich CM, McTiernan A, Bernstein L, Wayne S, Gilliland F,Baumgartner K, Baumgartner R, Ballard-Barbash R. Vitamin D insufficiency in a multiethnic cohort of breast cancersurvivors. Am J Clin Nutr. 2008 Jul;88(1):133-9.

Ng K, Meyerhardt JA, Wu K, Feskanich D, Hollis BW, Giovannucci EL, Fuchs CS. Circulating 25-hydroxyvitamin d levelsand survival in patients with colorectal cancer. J Clin Oncol. 2008 Jun 20;26(18):2984-91.

Nittke T, Selig S, Kallay E, Cross HS. Nutritional calcium modulates colonic expression of vitamin D receptor andpregnane X receptor target genes. Mol Nutr Food Res. 2008 Jun;52 Suppl 1:S45-51.


6/50

6 | P a g e

Norval M, Woods GM. Comment on "Hypothesis-Ultraviolet-B Irradiance and Vitamin D Reduce the Risk of ViralInfections and thus their Sequelae, Including Autoimmune Diseases and some Cancers" by W.B. Grant, Photochem.Photobiol. (2007). Photochem Photobiol. 2008 May-Jun;84(3):802-5.

Nrnberg B, Schadendorf D, Grtner B, Pfhler C, Herrmann W, Tilgen W, Reichrath J. Progression of malignantmelanoma is associated with reduced 25-hydroxyvitamin D serum levels. Exp Dermatol. 2008 Jul;17(7):627.

Obara W, Mizutani Y, Oyama C, Akaza H, Ishii N, Kohri K, Namiki M, Okuyama A, Shima H, Yokoyama M, Shuin T, MikiT, Watanabe Y, Fujioka T. Prospective study of combined treatment with interferon-alpha and active vitamin D forJapanese patients with metastatic renal cell carcinoma. Int J Urol. 2008 Jul 21. [Epub ahead of print]

Oberyszyn TM. Non-melanoma skin cancer: Importance of gender, immunosuppressive status and vitamin D. CancerLett. 2008 Mar 18;261(2):127-36.

Ochs-Balcom HM, Cicek MS, Thompson CL, Tucker TC, Elston RC, Plummer S, Casey G, Li L. Association of Vitamin DReceptor Gene Variants, Adiposity and Colon Cancer. Carcinogenesis. 2008 Sep;29(9):1788-93.

Oh EY, Wood PA, Du-Quiton J, Hrushesky WJ. Seasonal modulation of post-resection breast cancer metastasis. BreastCancer Res Treat. 2008 Sep;111(2):219-28.

Overcash JA. Vitamin d in older patients with cancer. Clin J Oncol Nurs. 2008 Aug;12(4):655-62.

Parisi E, Re JM, Cards A, Valcheva P, Piol-Felis C, Valdivielso JM, Fernndez E.

Vitamin D receptor levels in colorectal cancer Possible role of BsmI polymorphism. J Steroid Biochem Mol Biol. 2008Jul;111(1-2):87-90.

Peng X, Hawthorne M, Vaishnav A, St-Arnaud R, Mehta RG. 25-Hydroxyvitamin D(3) is a natural chemopreventive agentagainst carcinogen induced precancerous lesions in mouse mammary gland organ culture. Breast Cancer Res Treat.2008 Jan 20; [Epub ahead of print]

Prez-Lpez FR. Sunlight, the vitamin D endocrine system, and their relationships with gynaecologic cancer. Maturitas.2008 Feb 20;59(2):101-13.

Pilz S, Dobnig H, Winklhofer-Roob B, Riedmller G, Fischer JE, Seelhorst U, Wellnitz B, Boehm BO, Mrz W. Low SerumLevels of 25-Hydroxyvitamin D Predict Fatal Cancer in Patients Referred to Coronary Angiography. Cancer EpidemiolBiomarkers Prev. 2008 May;17(5):1228-33.

Porojnicu AC, Dahlback A, Moan J. Sun exposure and cancer survival in Norway: changes in the risk of death withseason of diagnosis and latitude. Adv Exp Med Biol. 2008;624:43-54.

Reichrath J, Nrnberg B. Solar UV-radiation, vitamin D and skin cancer surveillance in organ transplant recipients (OTRs)Adv Exp Med Biol. 2008;624:203-14.

Rohan TE et al. Low-Fat Dietary Pattern and Risk of Benign Proliferative Breast Disease: A Randomized, ControlledDietary Modification Trial. Cancer Prev Res first published on August 18, 2008 as doi:10.1158/1940-6207.CAPR-08-0003

Rossi M, McLaughlin JK, Lagiou P, Bosetti C, Talamini R, Lipworth L, Giacosa A, Montella M, Franceschi S, Negri E, LaVecchia C. Vitamin D intake and breast cancer risk: a case-control study in Italy. Ann Oncol. 2008 Aug 18. [Epub ahead ofprint]

Rosso S, Sera F, Segnan N, Zanetti R. Sun exposure prior to diagnosis is associated with improved survival in melanomapatients: Results from a long-term follow-up study of Italian patients. Eur J Cancer. 2008 June;44 (9):1275-1281.

Schwartz GG. Prostate cancer, serum parathyroid hormone, and the progression of skeletal metastases. CancerEpidemiol Biomarkers Prev. 2008 Mar;17(3):478-83.

Schwartz GG. Vitamin D and Intervention Trials in Prostate Cancer: From Theory to Therapy. Ann Epidemiol. 2008 Jul 9.[Epub ahead of print]


7/50

7 | P a g e

Serda RE, Bisoffi M, Thompson TA, Ji M, Omdahl JL, Sillerud LO. 1alpha,25-Dihydroxyvitamin D(3) down-regulatesexpression of prostate specific membrane antigen in prostate cancer cells. Prostate. 2008 Feb 4;68(7):773-783

Sinotte M, Rousseau F, Ayotte P, Dewailly E, Diorio C, Giguere Y, Berube S, Brisson J. Vitamin D receptorpolymorphisms (FokI, BsmI) and breast cancer risk: association replication in two case-control studies within FrenchCanadian population. Endocr Relat Cancer. 2008 Aug 21. [Epub ahead of print]

Skinner HG. Vitamin D for the treatment and prevention of pancreatic cancer. Cancer Biol Ther. 2008 Apr 10;7(3).

Soerjomataram I, Louwman WJ, Lemmens VE, Coebergh JW, de Vries E. Are Patients with Skin Cancer at Lower Risk ofDeveloping Colorectal or Breast Cancer? Am J Epidemiol. 2008 167: 1421-1429.

Stallings VA. Childhood cancer and vitamins: prevention and treatment. Pediatr Blood Cancer. 2008 Feb;50(2 Suppl):442-4; discussion 451.

Stolzenberg-Solomon RZ. Vitamin D and Pancreatic Cancer. Ann Epidemiol. 2008 May 24. [Epub ahead of print]

Theodoratou E, Farrington SM, Tenesa A, McNeill G, Cetnarskyj R, Barnetson RA, Porteous ME, Dunlop MG, CampbellH. Modification of the inverse association between dietary vitamin D intake and colorectal cancer risk by a FokI variantsupports a chemoprotective action of Vitamin D intake mediated through VDR binding. Int J Cancer. 2008 Aug 15. [Epubahead of print]

Thorne J, Campbell MJ. The vitamin D receptor in cancer. Proc Nutr Soc. 2008 May;67(2):115-27.

Torkko KC, van Bokhoven A, Mai P, Beuten J, Balic I, Byers TE, Hokanson JE, Norris JM, Barn AE, Lucia MS,Thompson IM, Leach RJ. VDR and SRD5A2 Polymorphisms Combine to Increase Risk for Prostate Cancer in Both Non-Hispanic White and Hispanic White Men. Clin Cancer Res. 2008 May 15;14(10):3223-3229.

Ulrich CM, Holmes RS. Shedding light on colorectal cancer prognosis: vitamin d and beyond. J Clin Oncol. 2008 Jun20;26(18):2937-9.

Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk in patients with different types of cancer. Acta Oncol. 2008 Jul 4:1-11. [Epub ahead of print]

Waltz P, Chodick G. Assessment of ecological regression in the study of colon, breast, ovary, non-Hodgkin's lymphoma,or prostate cancer and residential UV. Eur J Cancer Prev. 2008 Jun;17(3):279-86.

Wang C, Baumgartner RN, Yang D, Slattery ML, Murtaugh MA, Byers T, Hines LM, Giuliano AR, Baumgartner KB. Noevidence of association between breast cancer risk and dietary carotenoids, retinols, vitamin C and tocopherols inSouthwestern Hispanic and non-Hispanic White women. Breast Cancer Res Treat. 2008 Aug 1. [Epub ahead of print]

Wang-Gillam A, Miles DA, Hutchins LF. Evaluation of Vitamin D Deficiency in Breast Cancer Patients onBisphosphonates. Oncologist. 2008 Jul;13(7):821-7.

Weingarten M, Zalmanovici A, Yaphe J. Dietary calcium supplementation for preventing colorectal cancer andadenomatous polyps. Cochrane Database Syst Rev. 2008 Jan 23;(1):CD003548.

Wigle DT, Turner MC, Gomes J, Parent ME. Role of hormonal and other factors in human prostate cancer. J ToxicolEnviron Health B Crit Rev. 2008 Mar;11(3-4):242-59.

2007(176 papers (28>2)

Abbas S, Linseisen J, Chang-Claude J. Dietary vitamin d and calcium intake and premenopausal breast cancer risk in agerman case-control study. Nutr Cancer. 2007;59(1):54-61.


8/50

8 | P a g e

Abnet CC, Chen W, Dawsey SM, Wei WQ, Roth MJ, Lie B, Lu N, Taylor PR, Qiao YL. Serum 25(OH)-vitamin Dconcentration and risk of esophageal squamous dysplasia. Cancer Epidemiol Biomarkers Prev 2007;16 1889-93.

Abrahamsen B, Nielsen MF, Eskildsen P, Andersen JT, Walter S, Brixen K. Fracture risk in Danish men with prostatecancer: a nationwide register study. BJU Int. 2007 Oct;100(4):749-54.

Agic A, Xu H, Altgassen C, Noack F, Wolfler MM, Diedrich K, Friedrich M, Taylor RN, Hornung D. Relative expression of1,25-dihydroxyvitamin D3 receptor, vitamin D 1 alpha-hydroxylase, vitamin D 24-hydroxylase, and vitamin D 25-hydroxylase in endometriosis and gynecologic cancers. Reprod Sci. 2007 Jul;14(5):486-97.

Ahn J, Albanes D, Peters U, Schatzkin A, Lim U, Freedman M, Chatterjee N, Andriole GL, Leitzmann MF, Hayes RB; forthe Prostate, Lung, Colorectal, and Ovarian Trial Project Team. Dairy products, calcium intake, and risk of prostate cancerin the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev. 2007Dec;16(12):2623-30.

Alagbala AA, Moser MT, Johnson CS, Trump DL, Foster BA. Characterization of Vitamin D insensitive prostate cancercells. J Steroid Biochem Mol Biol. 2007 Mar;103(3-5):712-6.

Ali MM, Vaidya V. Vitamin D and cancer. J Cancer Res Ther. 2007 Oct-Dec;3(4):225-30.

Almquist M, Manjer J, Bondeson L, Bondeson AG. Serum calcium and breast cancer risk: results from a prospectivecohort study of 7,847 women. Cancer Causes Control. 2007 Aug;18(6):597-602.

Armstrong BK, Kricker A. Sun Exposure and Non-Hodgkin Lymphoma. Cancer Epidemiol Biomarkers Prev. 2007 16: 396-400.

Atkinson SA. Vitamin D status and bone biomarkers in childhood cancer. Pediatr Blood Cancer. 2007 Dec 6;50(S2):479-482.

Autier P, Gandini S. Vitamin D Supplementation and Total Mortality: A Meta-analysis of Randomized Controlled Trials.Arch Intern Med. 2007 Sep 10;167(16):1730-7. (2 ISI)

Aviner S, Dabby D, London D, Feinmesser M, Ash S, Steinberg R, Jakim I. Renal Cell Carcinoma in a Child Presented asBilateral Femur Neck Fractures Caused by Severe Vitamin D Deficiency. J Pediatr Hematol Oncol. 2007 Dec;29(12):848-850.

Becker S, Cordes T, Diesing D, Diedrich K, Friedrich M. Expression of 25 hydroxyvitamin D3-1alpha-hydroxylase inhuman endometrial tissue. J Steroid Biochem Mol Biol. 2007 Mar;103(3-5):771-5.

Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, Redfern CH, Fehrenbacher L, Saleh MN,Waterhouse DM, Carducci MA, Vicario D, Dreicer R, Higano CS, Ahmann FR, Chi KN, Henner WD, Arroyo A, Clow FW;

ASCENT Investigators. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placeboplus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol. 2007 Feb20;25(6):669-74. (9 ISI)

Beer TM, Javle MM, Ryan CW, Garzotto M, Lam GN, Wong A, Henner WD, Johnson CS, Trump DL. Phase I study ofweekly DN-101, a new formulation of calcitriol, in patients with cancer. Cancer Chemother Pharmacol. 2007

Apr;59(5):581-7. (2 ISI)

Ben-Shoshan M, Amir S, Dang DT, Dang LH, Weisman Y, Mabjeesh NJ. 1alpha,25-dihydroxyvitamin D3 (Calcitriol)inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells. Mol Cancer Ther.2007 Apr;6(4):1433-9.

Bertone-Johnson ER. Prospective studies of dietary vitamin D and breast cancer: more questions raised than answered.Nutr Rev. 2007 Oct;65(10):459-66.

Bikle DD. What is new in vitamin D: 2006-2007. Curr Opin Rheumatol. 2007 Jul;19(4):383-8.

Bonjour JP, Chevalley T, Fardellone P. Calcium intake and vitamin D metabolism and action, in healthy conditions and inprostate cancer. Br J Nutr. 2007 Apr;97(4):611-6. (1 GS)


9/50

9 | P a g e

Bosetti C, Scotti L, Maso LD, Talamini R, Montella M, Negri E, Ramazzotti V, Franceschi S, Vecchia CL. Micronutrientsand the risk of renal cell cancer: A case-control study from Italy. Int J Cancer. 2007 Feb 15;120(4):892-6.

Braverman AS. Evidence that high calcium and vitamin D intake decrease the risk of breast cancer in premenopausalwomen: implications for breast cancer prevention and screening. South Med J. 2007 Nov;100(11):1061-2.

Brisson J, Berube S, Diorio C, Sinotte M, Pollak M, Masse B. Synchronized seasonal variations of mammographic breastdensity and plasma 25-hydroxyvitamin D. Cancer Epidemiol Biomarkers Prev. 2007 May;16(5):929-33.

Brown DJ, Milroy R, Preston T, McMillan DC. The relationship between an inflammation-based prognostic score (GlasgowPrognostic Score) and changes in serum biochemical variables in patients with advanced lung and gastrointestinalcancer. J Clin Pathol. 2007 Jun;60(6):705-8.

Bruno RD, Njar VC. Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development. Bioorg MedChem. 2007 Aug 1;15(15):5047-60.

Byers S, Shah S. Vitamin D and the regulation of Wnt/beta-catenin signaling and innate immunity in colorectal cancer.Nutr Rev. 2007 Aug;65(8 Pt 2):S118-20.

Byrne B, Welsh J. Identification of novel mediators of Vitamin D signaling and 1,25(OH)2D3 resistance in mammary cells.J Steroid Biochem Mol Biol. 2007 Mar;103(3-5):703-7. (2 ISI)

Byrne BM, Welsh J. Altered thioredoxin subcellular localization and redox status in MCF-7 cells following 1,25-dihydroxyvitamin D3 treatment. J Steroid Biochem Mol Biol. 2005 Oct;97(1-2):57-64.

Chen S, Sims GP, Chen XX, Gu YY, Chen S, Lipsky PE. Modulatory effects of 1,25-dihydroxyvitamin D3 on human B celldifferentiation. J Immunol. 2007 Aug 1;179(3):1634-47.

Chen W, Dawsey SM, Qiao YL, Mark SD, Dong ZW, Taylor PR, Zhao P, Abnet CC. Prospective study of serum 25(OH)-vitamin D concentration and risk of oesophageal and gastric cancers. Br J Cancer. 2007 June 26;97:123-128.

Chung I, Karpf AR, Muindi JR, Conroy JM, Nowak NJ, Johnson CS, Trump DL. Epigenetic silencing of CYP24 in tumor-derived endothelial cells contributes to selective growth inhibition by calcitriol. J Biol Chem. 2007 Mar 23;282(12):8704-14

Cross HS. Extrarenal vitamin D hydroxylase expression and activity in normal and malignant cells: modification of

expression by epigenetic mechanisms and dietary substances. Nutr Rev. 2007 Aug;65(8 Pt 2):S108-12.

Davis CD, Hartmuller V, Freedman DM, Hartge P, Picciano MF, Swanson CA, Milner JA. Vitamin D and cancer: currentdilemmas and future needs. Nutr Rev. 2007 Aug;65(8 Pt 2):S71-4.

Davis CD, Dwyer JT. The "Sunshine Vitamin": Benefits Beyond Bone? J Natl Cancer Inst. 2007 Nov;99:1563-5.

Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat RevCancer. 2007 Sep;7(9):684-700. (15 ISI)

de Vries E, Soerjomataram I, Houterman S, Louwman MW, Coebergh JW. Decreased risk of prostate cancer after skincancer diagnosis: A protective role of ultraviolet radiation? Am J Epidemiol. 2007 165: 966-972. (2 GS)

Ding EL, Mehta S, Fawzi WW, Giovannucci EL. Interaction of estrogen therapy with calcium and vitamin Dsupplementation on colorectal cancer risk: Reanalysis of Women's Health Initiative randomized trial. Int J Cancer. 2007Dec 18;122(8):1690-1694.

Dizdar O, Harputluoglu H, Altundag K. Vitamin d intake and breast cancer risk in postmenopausal women. Arch InternMed. 2007 Dec 10;167(22):2532.

Eelen G, Gysemans C, Verlinden L, Vanoirbeek E, De Clercq P, Van Haver D, Mathieu1 C, Bouillon R, VerstuyfA. Mechanism and Potential of the Growth-Inhibitory Actions of Vitamin D and Ana-logs. Curr Med Chem.2007;14(17):1893-1910.


10/50

10 | P a g e

Faupel-Badger JM, Diaw L, Albanes D, Virtamo J, Woodson K, Tangrea JA. Lack of Association between Serum Levels of25-Hydroxyvitamin D and the Subsequent Risk of Prostate Cancer in Finnish Men. Cancer Epidemiol Biomarkers Prev.2007 Dec;16(12):2784-6.

Feldman D, Krishnan A, Moreno J, Swami S, Peehl DM, Srinivas S. Vitamin D inhibition of the prostaglandin pathway astherapy for prostate cancer. Nutr Rev. 2007 Aug;65(8 Pt 2):S113-5.

Fischer D, Seifert M, Becker S, Ludders D, Cordes T, Reichrath J, Friedrich M. 25-Hydroxyvitamin D3 1alpha-HydroxylaseSplice Variants in Breast Cell Lines MCF-7 and MCF-10. Cancer Genomics Proteomics. 2007 Jul-Aug;4(4):295-300.

Fleet JC. What have genomic and proteomic approaches told us about vitamin D and cancer? Nutr Rev. 2007 Aug;65(8Pt 2):S127-30.

Flugge J, Krusekopf S, Goldammer M, Osswald E, Terhalle W, Malzahn U, Roots I. Vitamin D receptor haplotypes protectagainst development of colorectal cancer. Eur J Clin Pharmacol. 2007 Nov;63(11):997-1005

Fraser DR. Exploration of possible mechanisms linking vitamin D status and dietary calcium to prostate cancer. Br J Nutr.2007 Apr;97(4):596-7.

Freedman DM, Looker AC, Chang SC, Graubard BI. Prospective study of serum vitamin D and cancer mortality in theUnited States. JNCI. 2007;99:1594-1602.

Froicu M, Cantorna MT. Vitamin D and the vitamin D receptor are critical for control of the innate immune response to

colonic injury. BMC Immunol. 2007 Mar 30;8:5.

Garland CF, Gorham ED, Mohr SB, Grant WB, Giovannucci EL, Lipkin M, Newmark H, Holick MF, Garland FC. VitaminD and prevention of breast cancer: Pooled analysis. J Steroid Biochem Mol Biol. 2007;103(3-5):708-11. (7 ISI, 10 GS)

Garland CF, Grant WB, Mohr SB, Gorham ED, Garland FC. What is the dose-response relationship between vitamin Dand cancer risk? Nutr Rev. 2007 Aug;65(8 Pt 2):S91-5.

Gilchrest BA. Sun protection and Vitamin D: three dimensions of obfuscation. J Steroid Biochem Mol Biol. 2007Mar;103(3-5):655-63. (2 ISI)

Giovannucci E. Strengths and limitations of current epidemiologic studies: vitamin D as a modifier of colon and prostatecancer risk. Nutr Rev. 2007 Aug;65(8 Pt 2):S77-9.

Giovannucci E. Epidemiological evidence for vitamin D and colorectal cancer. J Bone Miner Res. 2007 Dec;22 Suppl2:V81-5.

Gorham ED, Garland CF, Garland FC, Grant WB, Mohr SB, Lipkin M, Newmark HL, Giovannucci E, Wei M, Holick MF.Optimal vitamin d status for colorectal cancer prevention a quantitative meta analysis. Am J Prev Med. 2007Mar;32(3):210-6. (29 ISI, 17 GS)

Grant WB. Vitamin D and cancer risk among American Indians. Cancer Epidemiol Biomarkers Prev 2007;16:183.

Grant WB. An ecologic study of cancer mortality rates in Spain with respect to indices of solar UV irradiance and smoking.Int J Cancer. 2007;120:1123-7. (6 ISI, 7 GS)Note: I have a correction to this paper that I would be happy to supply. I should have done a multiple regression analysis.15 cancers show evidence of a UVB effect, not 17 reported.

Grant WB. A meta-analysis of second cancers after a diagnosis of nonmelanoma skin cancer: additional evidence thatsolar ultraviolet-B irradiance reduces the risk of internal cancers. J Steroid Biochem Mol 2007;103(3-5):668-674. (3 ISI)

Grant WB. Does Solar Ultraviolet Irradiation affect Cancer Mortality Rates in China? Asian Pac J Cancer Prev. 2007 Apr-Jun;8(2):236-42.

Grant WB. Roles of solar ultraviolet radiation and vitamin D in human health and how to obtain vitamin D. Expert RevDermatol. 2007;2(5):563-77.


11/50

11 | P a g e

Grant WB, Garland CF, Gorham ED. An estimate of cancer mortality rate reductions in Europe and the U.S. with 1000 I.U.of oral vitamin D per day. Rec Results Cancer Res. 2007;174:225-34.

Grant WB, Moan J, Reichrath J. Comment on "The effects on human health from stratospheric ozone depletion and itsinteractions with climate change" by M. Norval, A. P. Cullen, F. R. de Gruijl, J. Longstreth, Y. Takizawa, R. M. Lucas, F. P.Noonan and J. C. van der Leun, Photochem. Photobiol. Sci., 2007, 6, 232. Photochem Photobiol Sci. 2007 Aug;6(8):912-5.

Grau MV, Baron JA, Sandler RS, Wallace K, Haile RW, Church TR, Beck GJ, Summers RW, Barry EL, Cole BF, SnoverDC, Rothstein R, Mandel JS.Prolonged effect of calcium supplementation on risk of colorectal adenomas in a randomizedtrial. J Natl Cancer Inst. 2007 Jan 17;99(2):129. (3 ISI)

Han J, Colditz GA, Hunter DJ. Polymorphisms in the MTHFR and VDR genes and skin cancer risk. Carcinogenesis. 2007Feb;28(2):390-7. (2 ISI)

Herring PA, Ingels J, Palmieri G, Hasty KA. 1alpha,25-Dihydroxyvitamin D(3) enhances proliferation of rat prostate cancercells in the presence of living bone. J Steroid Biochem Mol Biol. 2007 Mar;103(3-5):737-41

Hewison M, Burke F, Evans KN, Lammas DA, Sansom DM, Liu P, Modlin RL, Adams JS. Extra-renal 25-hydroxyvitaminD(3)-1alpha-hydroxylase in human health and disease. J Steroid Biochem Mol Biol. 2007 Mar;103(3-5):316-21.

Holick MF. Vitamin D deficiency. N Engl J Med. 2007 Jul 19;357(3):266-81. Review. (4 GS)

Hosgood HD 3rd, Baris D, Zahm SH, Zheng T, Cross AJ. Diet and risk of multiple myeloma in Connecticut women.Cancer Causes Control. 2007 Dec;18(10):1065-76.

Hutchinson PE, Osborne JE. Do we need a revised public health policy on sun exposure? British Journal of Dermatology.2007;156 (4), 786788.

Ingles SA. Can diet and/or sunlight modify the relationship between vitamin D receptor polymorphisms and prostatecancer risk? Nutr Rev. 2007 Aug;65(8 Pt 2):S105-7.

Jacobs ET, Alberts DS, Benuzillo J, Hollis BW, Thompson PA, Martinez ME. Serum 25(OH)D levels, dietary intake ofvitamin D, and colorectal adenoma recurrence. J Steroid Biochem Mol 2007;103(3-5): 752-756.

Jacobs ET, Thompson PA, Martinez ME. Diet, Gender, and Colorectal Neoplasia. J Clin Gastroenterol. 2007

Sep;41(8):731-746.

Jimenez-Lara AM. Colorectal cancer: Potential therapeutic benefits of Vitamin D. Int J Biochem Cell Biol. 2007;39(4):672-7.

John EM, Koo J, Schwartz GG. Sun Exposure and Prostate Cancer Risk: Evidence for a Protective Effect of Early-LifeExposure. Cancer Epidemiol Biomarkers Prev 2007;16 1283-1286.

John EM, Schwartz GG, Koo J, Wang W, Ingles SA. Sun Exposure, Vitamin D Receptor Gene Polymorphisms, andBreast Cancer Risk in a Multiethnic Population. Am J Epidemiol. 2007 166: 1409-1419.

Kadiyska T, Yakulov T, Kaneva R, Nedin D, Alexandrova A, Gegova A, Savov A, Mitev V, Kremensky I. Vitamin D andestrogen receptor gene polymorphisms and the risk of colorectal cancer in Bulgaria. Int J Colorectal Dis. 2007

Apr;22(4):395-400.

Kinoshita S, Wagatsuma Y, Okada M. Geographical distribution for malignant neoplasm of the pancreas in relation toselected climatic factors in Japan. Int J Health Geogr. 2007; 6: 34.http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=1971256&blobtype=pdf

Knight JA, Lesosky M, Barnett H, Raboud JM, Vieth R. Vitamin D and Reduced Risk of Breast Cancer: A Population-Based Case-Control Study. Cancer Epidemiol Biomarkers Prev 2007;16: 422-429. (10 ISI, 1 GS)


12/50

12 | P a g e

Krishnan AV, Moreno J, Nonn L, Malloy P, Swami S, Peng L, Peehl DM, Feldman D. Novel pathways that contribute tothe anti-proliferative and chemopreventive activities of calcitriol in prostate cancer. J Steroid Biochem Mol Biol. 2007Mar;103(3-5):694-702. (2 ISI)

Krishnan AV, Swami S, Moreno J, Bhattacharyya RB, Peehl DM, Feldman D. Potentiation of the growth-inhibitory effectsof vitamin D in prostate cancer by genistein. Nutr Rev. 2007 Aug;65(8 Pt 2):S121-3.

Krishnan AV, Moreno J, Nonn L, Swami S, Peehl DM, Feldman D. Calcitriol as a chemopreventive and therapeutic agentin prostate cancer: role of anti-inflammatory activity. J Bone Miner Res. 2007 Dec;22 Suppl 2:V74-80.

Kutuzova GD, Deluca HF. 1,25-Dihydroxyvitamin D(3) regulates genes responsible for detoxification in intestine. ToxicolAppl Pharmacol. 2007 Jan 1;218(1):37-44. (2 ISI)

Lagunova Z, Porojnicu AC, Dahlback A, Berg JP, Beer TM, Moan J. Prostate cancer survival is dependent on season ofdiagnosis. Prostate. 2007 Sep 1;67(12):1362-70.

Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP. Vitamin D and calcium supplementation reducescancer risk: results of a randomized trial. Am J Clin Nutr. 2007 Jun;85(6):1586-91. (66 ISI, 40 GS)

Lappe JM, Heaney RP. Reply to RP Ojha et al. Am J Clin Nutr 2007 86: 1805-1806.

Larriba MJ, Valle N, Palmer HG, Ordonez-Moran P, Alvarez-Diaz S, Becker KF, Gamallo C, de Herreros AG, Gonzalez-Sancho JM, Munoz A. The inhibition of Wnt/beta-catenin signalling by 1alpha,25-dihydroxyvitamin D3 is abrogated by

Snail1 in human colon cancer cells. Endocr Relat Cancer. 2007 Mar;14(1):141-51.

Lechner D, Kllay E, Cross HS. 1alpha,25-dihydroxyvitamin D3 downregulates CYP27B1 and induces CYP24A1 in coloncells. Mol Cell Endocrinol. 2007 Jan 15;263(1-2):55-64.

Lee SS, Crabb SJ, Janghra N, Carlberg C, Williams AC, Cutress RI, Packham G, Hague A. Subcellular localisation ofBAG-1 and its regulation of vitamin D receptor-mediated transactivation and involucrin expression in oral keratinocytes:implications for oral carcinogenesis. Exp Cell Res. 2007 Sep 10;313(15):3222-38.

Li C, Liu Z, Zhang Z, Strom SS, Gershenwald JE, Prieto VG, Lee JE, Ross MI, Mansfield PF, Cormier JN, Duvic M,Grimm EA, Wei Q. Genetic variants of the vitamin D receptor gene alter risk of cutaneous melanoma. J Invest Dermatol.2007 Feb;127(2):276-80. (2 ISI)

Li H, Stampfer MJ, Hollis JBW, Mucci LA, Gaziano JM, Hunter

D, Giovannucci EL, Jing Ma

J. A prospective study ofplasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med. 2007;4(3): e103. (3ISI)

Lin J, JoAnn E. Manson; I-Min Lee; Nancy R. Cook; Julie E. Buring; Shumin M. Zhang. Intakes of Calcium and Vitamin Dand Breast Cancer Risk in Women.Arch Intern Med. 2007;167:1050-1059. (18 ISI)

Lucas RM. Critically evaluating the evidence: risk versus benefit for sun exposure. Expert Review of Dermatology,October 2007;2:515-518.

Lurie G, Wilkens LR, Thompson PJ, McDuffie KE, Carney ME, Terada KY, Goodman MT. Vitamin d receptor genepolymorphisms and epithelial ovarian cancer risk. Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2566-71.

Matusiak D, Benya RV. CYP27A1 and CYP24 Expression as a Function of Malignant Transformation in the Colon. JHistochem Cytochem. 2007 Dec;55(12):1257-64.

McCullough ML, Stevens VL, Diver WR, Feigelson HS, Rodriguez C, Bostick RM, Thun MJ, Calle EE. Vitamin D pathwaygene polymorphisms, diet, and risk of postmenopausal breast cancer: a nested case-control study. Breast Cancer Res.2007;9(1):R9. (7 ISI)

Mernitz H, Smith DE, Wood RJ, Russell RM, Wang XD. Inhibition of lung carcinogenesis by 1alpha,25-dihydroxyvitaminD(3) and 9-cis retinoic acid in the A/J mouse model: Evidence of retinoid mitigation of vitamin D toxicity. Int J Cancer.2007 Apr 1;120(7):1402-9.


13/50

13 | P a g e

Mikhak B, Hunter DJ, Spiegelman D, Platz EA, Hollis BW, Giovannucci E. Vitamin D receptor (VDR) gene polymorphismsand haplotypes, interactions with plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, and prostate cancer risk.Prostate. 2007 Jun 15;67(9):911-23.

Mittal RD, Manchanda PK, Bhat S, Bid HK. Association of vitamin-D receptor (Fok-I) gene polymorphism with bladdercancer in an Indian population. BJU Int. 2007 Apr;99(4):933-7.

Moan J, Porojnicu A, Lagunova Z, Berg JP, Dahlback A. Colon cancer: Prognosis for different latitudes, age groups andseasons in Norway. J Photochem Photobiol B: Biol. 2007;89:148-55.

Mohr SB, Garland CF, Gorham ED, Grant WB, Garland FC. Is ultraviolet B irradiance inversely associated with incidencerates of endometrial cancer: an ecological study of 107 countries. Prev Med. 2007 Nov;45(5):327-31.

Mordan-McCombs S, Valrance M, Zinser G, Tenniswood M, Welsh J. Calcium, vitamin D and the vitamin D receptor:impact on prostate and breast cancer in preclinical models. Nutr Rev. 2007 Aug;65(8 Pt 2):S131-3.

Mullin GE, Dobs A. Vitamin D and its role in cancer and immunity: a prescription for sunlight. Nutr Clin Pract. 2007Jun;22(3):305-22. (2 ISI, 1 GS)

Murillo G, Matusiak D, Benya RV, Mehta RG. Chemopreventive efficacy of 25-hydroxyvitamin D3 in colon cancer. JSteroid Biochem Mol 2007;103(3-5):763-767.

Nasri H, Baradaran A. The influence of serum 25-hydroxy vitamin D levels on Helicobacter Pylori Infections in patients

with end-stage renal failure on regular hemodialysis. Saudi J Kidney Dis Transpl. 2007 Jun;18(2):215-9.

Nielsen LR, Mosekilde L. [Vitamin D and breast cancer] Ugeskr Laeger. 2007 Apr 2;169(14):1299-302. Review. Danish.

Norsa A, Martino V. Somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide inchemotherapy-pretreated patients with advanced lung adenocarcinoma and low performance status. Cancer BiotherRadiopharm. 2007 Feb;22(1):50-5.

Norval M, de Gruijl FR. Reply to the 'Comment on "The effects on human health from stratospheric ozone depletion andits interactions with climate change"' by W. B. Grant, J. Moan and J. Reichrath, Photochem. Photobiol. Sci., 2007, 6, DOI:10.1039/b705482c. Photochem Photobiol Sci. 2007 Aug;6(8):916-8. (2 ISI)

Obara W, Suzuki Y, Kato K, Tanji S, Konda R, Fujioka T. Vitamin D receptor gene polymorphisms are associated with

increased risk and progression of renal cell carcinoma in a Japanese population. Int J Urol. 2007 Jun;14(6):483-7.

Obara W, Konda R, Akasaka S, Nakamura S, Sugawara A, Fujioka T. Prognostic Significance of Vitamin D Receptor andRetinoid X Receptor Expression in Renal Cell Carcinoma. J Urol. 2007 Oct;178(4 Pt 1):1497-503.

Oh K, Willett WC, Wu K, Fuchs CS, Giovannucci EL. Calcium and Vitamin D Intakes in Relation to Risk of DistalColorectal Adenoma in Women. Am J Epidemiol. 2007 165: 1178-1186. (2 ISI)

Ojha RP, Felini MJ, Fischbach LA. Vitamin D for cancer prevention: valid assertion or prematuer anointment? Am J ClinNutr. 2007; 85:1804-5.

O'Keefe SJ, Chung D, Mahmoud N, Sepulveda AR, Manafe M, Arch J, Adada H, van der Merwe T. Why do AfricanAmericans get more colon cancer than Native Africans? J Nutr. 2007 Jan;137(1 Suppl):175S-182S. (3 ISI)

Otani T, Iwasaki M, Sasazuki S, Inoue M, Tsugane S. Plasma vitamin D and risk of colorectal cancer: the Japan PublicHealth Center-Based Prospective Study. Br J Cancer. 2007 Jul 31;97(3):446-51.

Ozbek U, Kandilci A, van Baal S, Bonten J, Boyd K, Franken P, Fodde R, Grosveld GC. SET-CAN, the product of thet(9;9) in acute undifferentiated leukemia, causes expansion of early hematopoietic progenitors and hyperproliferation ofstomach mucosa in transgenic mice. Am J Pathol. 2007 Aug;171(2):654-66.

Park SY, Murphy SP, Wilkens LR, Nomura AM, Henderson BE, Kolonel LN. Calcium and Vitamin D Intake and Risk ofColorectal Cancer: The Multiethnic Cohort Study. Am J Epidemiol. 2007 165: 784-93. (10 ISI)


14/50

14 | P a g e

Park SY, Murphy SP, Wilkens LR, Stram DO, Henderson BE, Kolonel LN. Calcium, vitamin D, and dairy product intakeand prostate cancer risk: The Multiethnic Cohort Study. Am J Epidemiol. 2007 Dec 1;166(11):1270-1279.

Patino-Garcia B, Arroyo C, Rangel-Villalobos H, Soto-Vega E, Velarde-Felix JS, Gabilondo F, Sandoval-Ramirez L,Figuera LE. Association between polymorphisms of the androgen and vitamin D receptor genes with prostate cancer riskin a Mexican population. Rev Invest Clin. 2007 Jan-Feb;59(1):25-31.

Pendas-Franco N, Gonzalez-Sancho JM, Suarez Y, Aguilera O, Steinmeyer A, Gamallo C, Berciano MT, Lafarga M,Munoz A. Vitamin D regulates the phenotype of human breast cancer cells. Differentiation. 2007 Mar;75(3):193-207. (8ISI)

Perez-Fernandez, R.; Seoane, S.; Garcia-Caballero, T.; Segura, C.; Macia, M. Vitamin D, Pit-1, GH, and PRL: PossibleRoles in Breast Cancer Development. Current Medicinal Chemistry, 2007;14( 29):3051-8.

Peng X, Mehta RG. Differential expression of prohibitin is correlated with dual action of Vitamin D as a proliferative andantiproliferative hormone in breast epithelial cells. J Steroid Biochem Mol Biol. 2007 Mar;103(3-5):446-50.

Petridou ET, Dikalioti SK, Skalkidou A, Andrie E, Dessypris N, Trichopoulos D; The Childhood Hematology-OncologyGroup. Sun exposure, birth weight, and childhood lymphomas: a case control study in Greece. Cancer Causes Control.2007 Nov;18(9):1031-1037.

Porojnicu AC, Lagunova Z, Robsahm TE, Berg JP, Dahlback A, Moan J. Changes in risk of death from breast cancer withseason and latitude: Sun exposure and breast cancer survival in Norway. Breast Cancer Res Treat. 2007

May;102(3):323-8. (2 ISI)

Porojnicu AC, Robsahm TE, Dahlback A, Berg JP, Christiani D, Bruland OS, Moan J. Seasonal and geographicalvariations in lung cancer prognosis in Norway Does Vitamin D from the sun play a role? Lung Cancer. 2007Mar;55(3):263-70. (2 ISI, 2 GS)

Porojnicu A, Robsahm TE, Berg JP, Moan J. Season of diagnosis is a predictor of cancer survival. Sun-induced vitamin Dmay be involved: A possible role of sun-induced Vitamin D. J Steroid Biochem Mol 2007;103(3-5): 675-678. (8 ISI)

Povey JE, Darakhshan F, Robertson K, Bisset Y, Mekky M, Rees J, Doherty V, Kavanagh G, Anderson N, Campbell H,MacKie RM, Melton DW. DNA repair gene polymorphisms and genetic predisposition to cutaneous melanoma.Carcinogenesis. 2007 May;28(5):1087-93.

Purdue MP, Lan Q, Kricker A, Vajdic CM, Rothman N, Armstrong BK. Vitamin D receptor gene polymorphisms and risk ofnon-Hodgkin's lymphoma. Haematologica. 2007 Aug;92(8):1145-6.

Purdue MP, Hartge P, Davis S, et al. Sun exposure, vitamin D receptor gene polymorphisms and risk of non-Hodgkinlymphoma. Cancer Causes Control. 2007 18(9):989-99

Reichrath J, Lehmann B, Carlberg C, Varani J, Zouboulis CC. Vitamins as hormones. Horm Metab Res. 2007Feb;39(2):71-84. Review. (3 ISI)

Reichrath J. Vitamin D and the skin: an ancient friend, revisited. Exp Dermatol. 2007 Jul;16(7):618-25.

Reichrath J, Rech M, Moeini M, Meese E, Tilgen W, Seifert M. In vitro comparison of the vitamin D endocrine system in1,25(OH)2D3-responsive and -resistant melanoma cells. Cancer Biol Ther. 2007 Jan;6(1):48-55.

Robien K, Cutler GJ, Lazovich D. Vitamin D intake and breast cancer risk in postmenopausal women: the Iowa Women'sHealth Study. Cancer Causes Control. 2007 Sep;18(7):775-82. (1 ISI)

Rohan T. Epidemiological studies of vitamin D and breast cancer. Nutr Rev. 2007 Aug;65(8 Pt 2):S80-3.

Rukin NJ, Luscombe C, Moon S, Bodiwala D, Liu S, Saxby MF, Fryer AA, Alldersea J, Hoban PR, Strange RC. Prostatecancer susceptibility is mediated by interactions between exposure to ultraviolet radiation and polymorphisms in the 5'haplotype block of the vitamin D receptor gene. Cancer Lett. 2007 Mar 18;247(2):328-335. (5 ISI, 3 GS)


15/50

15 | P a g e

Rukin NJ, Zeegers MP, Ramachandran S, Luscombe CJ, Liu S, Saxby M, Lear J, Strange RC. A comparison of sunlightexposure in men with prostate cancer and basal cell carcinoma. Br J Cancer. 2007 Feb 12;96(3):523-528.

Rukin NJ, Strange RC. What are the frequency, distribution, and functional effects of vitamin D receptor polymorphismsas related to cancer risk? Nutr Rev. 2007 Aug;65(8 Pt 2):S96-101. (3 ISI)

Rukin N, Blagojevic M, Luscombe CJ, Liu S, Saxby MF, Ramachandran S, Fryer AA, Jones PW, Strange RC.Associations between timing of exposure to ultraviolet radiation, T-stage and survival in prostate cancer. Cancer DetectPrev. 2007;31(6):443-9

Ryan-Harshman M, Aldoori W. Diet and colorectal cancer: Review of the evidence. Can Fam Physician. 2007Nov;53(11):1913-20.

Santonocito, C., R. Capizzi, P. Concolino, M.M. Lavieri, A. Paradisi, S. Gentileschi, E. Torti, S. Rutella, S. Rocchetti, A. DCarlo, E. Di Stasio, F. Ameglio, C. Zuppi, E. Capoluongo. Association between cutaneous melanoma, Breslow thicknessand vitamin D receptor BsmI polymorphism. Br J Dermatol. 2007;156:277.

Santos Arrontes D, Garcia Gonzalez JI, Martin Munoz MP, Castro Pita M, Manas Pelillo A, Paniagua Andres P. [Will theclimate change affect the mortality from prostate cancer?] Arch Esp Urol. 2007 Mar;60(2):119-23. Spanish.

Schumann SA, Ewigman B. Double-dose vitamin D lowers cancer risk in women over 55. J Fam Pract. 2007Nov;56(11):907-910.

Schwalfenberg G. Not enough vitamin D: health consequences for Canadians. Can Fam Physician. 2007 May;53(5):841-54. Review.

Schwartz GG. The Cocaine Blues and Other Problems in Epidemiologic Studies of Vitamin D and Cancer. Nutr Cancer.2007;65(8):S75-S76.

Schwartz GG, Skinner HG. Vitamin D status and cancer: new insights. Curr Opin Clin Nutr Metab Care. 2007 Jan;10(1):6-11. (14 ISI, 4 GS)

Schwartz GG, Porta M. Vitamin D, ecologic studies and endometrial cancer. Prev Med. 2007 Nov;45(5):323-4.

Seubwai W, Wongkham C, Puapairoj A, Khuntikeo N, Wongkham S. Overexpression of vitamin D receptor indicates agood prognosis for cholangiocarcinoma: implications for therapeutics. Cancer. 2007 Jun 15;109(12):2497-505.

Sigmundsdottir H, Pan J, Debes GF, Alt C, Habtezion A, Soler D, Butcher EC. DCs metabolize sunlight-induced vitaminD3 to 'program' T cell attraction to the epidermal chemokine CCL27. Nat Immunol. 2007 Mar;8(3):285-293.

Sinclair C. Vitamin D--an emerging issue in skin cancer control. Implications for public health practice based on theAustralian experience. Recent Results Cancer Res. 2007;174:197-204. Review.

Slattery ML, Wolff RK, Herrick JS, Caan BJ, Potter JD. IL6 genotypes and colon and rectal cancer. Cancer CausesControl. 2007 Dec;18(10):1095-105.

Slattery ML. Vitamin D receptor gene (VDR) associations with cancer. Nutr Rev. 2007 Aug;65(8 Pt 2):S102-4.

Slattery ML, Herrick J, Wolff RK, Caan BJ, Potter JD, Sweeney C. CDX2 VDR Polymorphism and Colorectal Cancer.Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2752-5.

Soni LK, Hou L, Gapstur SM, Evens AM, Weisenburger DD, Chiu BC. Sun exposure and non-Hodgkin lymphoma: Apopulation-based, case-control study. Eur J Cancer. 2007 Nov;43(16):2388-95.

Spina CS, TonL, Yao

M, Maehr

H, Wolfe

MM, Uskokovic

M, Adorini

L, M.F. Holick

MF. Selective vitamin D receptor

modulators and their effects on colorectal tumor growth. J Steroid Biochem Mol 2007;103(3-5): 757-762.

Stallings VA. Childhood cancer and vitamins: Prevention and treatment. Pediatr Blood Cancer. 2007 Dec 6;50(S2):442-444.


16/50

16 | P a g e

Taghizadeh F, Tang MJ, Tai IT. Synergism between vitamin D and secreted protein acidic and rich in cysteine-inducedapoptosis and growth inhibition results in increased susceptibility of therapy-resistant colorectal cancer cells tochemotherapy. Mol Cancer Ther. 2007 Jan;6(1):309-17.

Tan J, Dwivedi PP, Anderson P, Nutchey BK, O'Loughlin P, Morris HA, May BK, Ferrante A, Hii CS. Antineoplastic agentstarget the 25-hydroxyvitamin D3 24-hydroxylase messenger RNA for degradation: implications in anticancer activity. MolCancer Ther. 2007 Dec;6(12):3131-8.

Tezal M, DDS, PhD; Maureen A. Sullivan, DDS; Mary E. Reid, PhD; James R. Marshall, PhD; Andrew Hyland, PhD;Thom Loree, MD; Cheryl Lillis, BS; Linda Hauck, BA; Jean Wactawski-Wende, PhD; Frank A. Scannapieco, DMD, PhD.Chronic Periodontitis and the Risk of Tongue Cancer.Arch Otolaryngol Head Neck Surg. 2007;133:450-454.

Timonen T, Nyh S, Koskela T, Pukkala E. Are sunlight deprivation and influenza epidemics associated with the onset ofacute leukemia? Haematologica. 2007 Nov;92(11):1553-6.

Ting HJ, Bao BY, Reeder JE, Messing EM, Lee YF. Increased Expression of Corepressors in Aggressive Androgen-Independent Prostate Cancer Cells Results in Loss of 1{alpha},25-Dihydroxyvitamin D3 Responsiveness. Mol CancerRes. 2007 Sep;5(9):967-80.

Trabert B, Malone KE, Daling JR, Doody DR, Bernstein L, Ursin G, Marchbanks PA, Strom BL, Humphrey MC, OstranderEA. Vitamin D receptor polymorphisms and breast cancer risk in a large population-based case control study ofCaucasian and African-American women. Breast Cancer Res. 2007 Dec 7;9(6):R84.

Tseng M, Byrne C, Evers KA, Daly MB. Dietary intake and breast density in high-risk women: a cross-sectional study.Breast Cancer Res. 2007 Oct 19;9(5):R72.

Tuohimaa P, Tenkanen L, Syvala H, Lumme S, Hakulinen T, Dillner J, Hakama M. Interaction of Factors Related to theMetabolic Syndrome and Vitamin D on Risk of Prostate Cancer. Cancer Epidemiol Biomarkers Prev 2007;16 302-307. (2GS)

Tuohimaa P, Pukkala E, Scelo G, Olsen JH, Brewster DH, Hemminki K, Tracey E, Weiderpass E, Kliewer EV, Pompe-Kirn V, McBride ML, Martos C, Chia KS, Tonita JM, Jonasson JG, Boffetta P, Brennan P. Does solar exposure, asindicated by the non-melanoma skin cancers, protect from solid cancers: Vitamin D as a possible explanation. Eur JCancer. 2007 May 29;43:1701-1712. (2 ISI, 1 GS)

Tworoger SS, I-Min Lee, Julie E. Buring, Bernard Rosner, Bruce W. Hollis, and Susan E. Hankinson. Plasma 25-

Hydroxyvitamin D and 1,25-Dihydroxyvitamin D and Risk of Incident Ovarian Cancer. Cancer Epidemiol Biomarkers Prev2007;16: 783-788. (2 ISI)

Valrance ME, Brunet AH, Welsh J. VDR Dependent Inhibition of Mammary Tumor Growth by EB1089 and UV Radiationin vivo. Endocrinology. 2007 Oct;148(10):4887-94.

Van Renterghem D. Lung cancer survival: vitamin d could be just a marker of physical fitness. J Clin Oncol. 2007 Dec1;25(34):5537-8.

van der Rhee HJ, de Vries E, Coebergh JW. [Favourable and unfavourable effects of exposure to sunlight] Ned TijdschrGeneeskd. 2007 Jan 13;151(2):118-22. Review. Dutch.

Vollmer RT. Solar elastosis in cutaneous melanoma. Am J Clin Pathol. 2007 Aug;128(2):260-4.

Wang JH, Tuohimaa P. Regulation of 17beta-hydroxysteroid dehydrogenase type 2, type 4 and type 5 by calcitriol, LXRagonist and 5alpha-dihydrotestosterone in human prostate cancer cells. J Steroid Biochem Mol Biol. 2007 Oct;107(1-2):100-5.

Wang X, Wang TT, White JH, Studzinski GP. Expression of human kinase suppressor of Ras 2 (hKSR-2) gene in HL60leukemia cells is directly upregulated by 1,25-dihydroxyvitamin D(3) and is required for optimal cell differentiation. ExpCell Res. 2007 Aug 15;313(14):3034-45.

Weihkopf T, Becker N, Nieters A, Mester B, Deeg E, Elsner G, Blettner M, Seidler A. Sun exposure and malignantlymphoma: A population-based case-control study in Germany. Int J Cancer.2007 Feb 20;120(11):2445-2451.


17/50

17 | P a g e

Welsh J. Vitamin D and prevention of breast cancer. Acta Pharmacol Sin. 2007 Sep;28(9):1373-82.

Wedren S, Magnusson C, Humphreys K, Melhus H, Kindmark A, Stiger F, Branting M, Persson I, Baron J, Weiderpass E.Associations between Androgen and Vitamin D Receptor Microsatellites and Postmenopausal Breast Cancer. CancerEpidemiol Biomarkers Prev. 2007 Sep;16(9):1775-83.

Weigel NL. Interactions between vitamin D and androgen receptor signaling in prostate cancer cells. Nutr Rev. 2007Aug;65(8 Pt 2):S116-7.

Welsh J. Targets of vitamin D receptor signaling in the mammary gland. J Bone Miner Res. 2007 Dec;22 Suppl 2:V86-90.

Wu FS, Zheng SS, Wu LJ, Teng LS, Ma ZM, Zhao WH, Wu W. Calcitriol inhibits the growth of MHCC97 heptocellular celllines by down-modulating c-met and ERK expressions. Liver Int. 2007 Jun;27(5):700-7.

Wu K, Feskanich D, Fuchs CS, Willett WC, Hollis BW, Giovannucci EL. A Nested Case-Control Study of Plasma 25-Hydroxyvitamin D Concentrations and Risk of Colorectal Cancer. J Natl Cancer Inst. 2007 July; 99: 1120-1129.

Yang K, Lipkin M, Newmark H, Rigas B, Daroqui C, Maier S, Augenlicht L. Molecular targets of calcium and vitamin D inmouse genetic models of intestinal cancer. Nutr Rev. 2007 Aug;65(8 Pt 2):S134-7.

Yaylim-Eraltan I, Arzu Ergen H, Arikan S, Okay E, Ozturk O, Bayrak S, Isbir T. Investigation of the VDR genepolymorphisms association with susceptibility to colorectal cancer. Cell Biochem Funct. 2007 Jan 23;25(6):731-737.

Zhang Y, Holford TR, Leaderer B, Boyle P, Zhu Y, Wang R, Zou K, Zhang B, Wise JP Sr, Qin Q, Kilfoy B, Han J, Zheng TUltraviolet Radiation Exposure and Risk of Non-Hodgkin's Lymphoma. Am J Epidemiol. 2007 Jun 1;165(11):1255-64.

Zhou W, Heist RS, Liu G, Asomaning K, Neuberg DS, Hollis BW, Wain JC, Lynch TJ, Giovannucci E, Su L, Christiani DC.Circulating 25-hydroxyvitamin d levels predict survival in early-stage non-small-cell lung cancer patients. J Clin Oncol.2007 Feb 10;25(5):479-85.

2006(111 papers, 45>5)

Abedin SA, Banwell CM, Colston KW, Carlberg C, Campbell MJ. Epigenetic corruption of VDR signalling in malignancy.Anticancer Res. 2006 Jul-Aug;26(4A):2557-66.

Anderson MG, Nakane M, Ruan X, Kroeger PE, Wu-Wong JR. Expression of VDR and CYP24A1 mRNA in humantumors. Cancer Chemother Pharmacol. 2006 Jan;57(2):234-40. (7 ISI)

Andersson P, Varenhorst E, Soderkvist P. Androgen receptor and vitamin D receptor gene polymorphisms and prostatecancer risk. Eur J Cancer. 2006 Nov;42(16):2833-7.

Armstrong BK. Commentary: seeing the light. Int J Epidemiol. 2006 Apr;35(2):231-2.

Banwell CM, MacCartney DP, Guy M, Miles AE, Uskokovic MR, Mansi J, Stewart PM, O'Neill LP, Turner BM, Colston KW

Campbell MJ. Altered nuclear receptor corepressor expression attenuates vitamin D receptor signaling in breast cancercells. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2004-13. (17 ISI)

Bao BY, Yeh SD, Lee YF. 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell invasion via modulation of selectiveproteases. Carcinogenesis. 2006 Jan;27(1):32-42. (8 ISI, 3 GS)

Bao BY, Yao J, Lee YF. 1alpha, 25-dihydroxyvitamin D3 suppresses interleukin-8-mediated prostate cancer cellangiogenesis. Carcinogenesis. 2006 Sep;27(9):1883-93.

Beer TM, Myrthue A. Calcitriol in the treatment of prostate cancer. Anticancer Res. 2006 Jul-Aug;26(4A):2647-51. (7 ISI)


18/50

18 | P a g e

Berndt SI, Dodson JL, Huang WY, Nicodemus KK. A systematic review of vitamin D receptor gene polymorphisms andprostate cancer risk. J Urol. 2006 May;175(5):1613-23. (1 ISI, 3 GS)

Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B. Estimation of optimal serumconcentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr. 2006 Jul;84(1):18-28. (33 ISI, 38 GS)

Boscoe FP, Schymura MJ. Solar ultraviolet-B exposure and cancer incidence and mortality in the United States, 1993-2000. BMC Cancer. 2006;6:264. (10 November 2006) (5 ISI, 6 GS)

Bouillon R, Eelen G, Verlinden L, Mathieu C, Carmeliet G, Verstuyf A. Vitamin D and cancer. J Steroid Biochem Mol Biol.2006 Dec;102(1-5):156-62. (19 ISI)

Campbell MJ, Adorini L. The vitamin D receptor as a therapeutic target. Expert Opin Ther Targets. 2006 Oct;10(5):735-48

Chang ET, Balter KM, Torrang A, Smedby KE, Melbye M, Sundstrom C, Glimelius B, Adami HO. Nutrient intake and riskof non-Hodgkin's lymphoma. Am J Epidemiol. 2006 Dec 15;164(12):1222-32.

Christakos S, Dhawan P, Shen Q, Peng X, Benn B, Zhong Y. New insights into the mechanisms involved in thepleiotropic actions of 1,25dihydroxyvitamin D3. Ann N Y Acad Sci. 2006 Apr;1068:194-203. (3 ISI)

Cicek MS, Liu X, Schumacher FR, Casey G, Witte JS. Vitamin D receptor genotypes/haplotypes and prostate cancer risk.Cancer Epidemiol Biomarkers Prev. 2006 Dec;15(12):2549-52.

Colli JL, Colli A. International comparisons of prostate cancer mortality rates with dietary practices and sunlight levels.Urol Oncol. 2006 May-Jun;24(3):184-94. (1 ISI)

Colston KW, Lowe LC, Mansi JL, Campbell MJ. Vitamin D status and breast cancer risk. Anticancer Res. 2006 Jul-Aug;26(4A):2573-80. (1 ISI)

Cross HS. Commentary: from epidemiology to molecular biologyvitamin D and colorectal cancer prevention. Int JEpidemiol. 2006 Apr;35(2):225-7. (2 ISI, 5 GS)

Cui Y, Rohan TE. Vitamin D, Calcium, and Breast Cancer Risk: A Review.Cancer Epidemiol Biomarkers Prev 2006 15:1427-1437. (18 ISI)

de Lyra EC, da Silva IA, Katayama ML, Brentani MM, Nonogaki S, Goes JC, Folgueira MA. 25(OH)D3 and 1,25(OH)2D3

serum concentration and breast tissue expression of 1alpha-hydroxylase, 24-hydroxylase and Vitamin D receptor inwomen with and without breast cancer. J Steroid Biochem Mol Biol. 2006 Aug;100(4-5):184-92.

Diesing D, Cordes T, Fischer D, Diedrich K, Friedrich M. Vitamin D--metabolism in the human breast cancer cell lineMCF-7. Anticancer Res. 2006 Jul-Aug;26(4A):2755-9.

Diorio C, Berube S, Byrne C, Masse B, Hebert-Croteau N, Yaffe M, Cote G, Pollak M, Brisson J. Influence of insulin-likegrowth factors on the strength of the relation of vitamin D and calcium intakes to mammographic breast density. CancerRes. 2006 Jan 1;66(1):588-97. (5 ISI)

Egan KM. Commentary: sunlight, vitamin D, and the cancer connection revisited. Int J Epidemiol. 2006 Apr;35(2):227-30.(2 ISI, 6 GS)

Flanagan JN, Young MV, Persons KS, Wang L, Mathieu JS, Whitlatch LW, Holick MF, Chen TC. Vitamin D metabolism inhuman prostate cells: implications for prostate cancer chemoprevention by vitamin D. Anticancer Res. 2006 Jul-

Aug;26(4A):2567-72. (1 ISI)

Friedrich M, Diesing D, Cordes T, Fischer D, Becker S, Chen TC, Flanagan JN, Tangpricha V, Gherson I, Holick MF,Reichrath J. Analysis of 25-hydroxyvitamin D3-1alpha-hydroxylase in normal and malignant breast tissue. Anticancer Res2006 Jul-Aug;26(4A):2615-20.

Garland CF, Garland FC, Gorham ED, Lipkin M, Newmark H, Mohr SB, Holick MF. The role of vitamin D in cancerprevention. Am J Public Health. 2006 Feb;96(2):252-61. (90 ISI; 67 GS)


19/50

19 | P a g e

Garland CF, Garland FC. Do sunlight and vitamin D reduce the likelihood of colon cancer? Int J Epidemiol. 2006Apr;35(2):217-20. (8 ISI)

Garland CF, Mohr SB, Gorham ED, Grant WB, Garland FC. Role of ultraviolet-B irradiance and vitamin D in theprevention of ovarian cancer. Am J Prev Med. 2006 Dec;31(6):512-4.

Gilad LA, Tirosh O, Schwartz B. Phytoestrogens regulate transcription and translation of vitamin D receptor in coloncancer cells. J Endocrinol. 2006 Nov;191(2):387-98.

Giovannucci E. The epidemiology of vitamin D and colorectal cancer: recent findings. Curr Opin Gastroenterol. 2006Jan;22(1):24-9. (23 ISI, 18 GS)

Giovannucci E, Liu Y, Stampfer MJ, Willett WC. A prospective study of calcium intake and incident and fatal prostatecancer. Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):203-10. (10 ISI)

Giovannucci E. Commentary: vitamin D and colorectal cancertwenty-five years later. Int J Epidemiol. 2006Apr;35(2):222-4. (2 ISI)

Giovannucci E, Liu Y, Rimm EB, Hollis BW, Fuchs CS. Stampfer MJ, Willett WH. Prospective study of predictors ofvitamin D status and cancer incidence and mortality in men. JNCI 2006; 98:451-9. (110 ISI, 56 GS)

Giovannucci E, Liu Y, Willett WC. Cancer incidence and mortality and vitamin D in black and white male healthprofessionals. Cancer Epidemiol Biomarkers Prev. 2006 Dec;15(12):2467-72.

Gombart AF, Luong QT, Koeffler HP. Vitamin D compounds: activity against microbes and cancer. Anticancer Res. 2006Jul-Aug;26(4A):2531-42.

Gonzalez-Sancho JM, Larriba MJ, Ordonez-Moran P, Palmer HG, Munoz A. Effects of 1alpha,25-dihydroxyvitamin D3 inhuman colon cancer cells. Anticancer Res. 2006 Jul-Aug;26(4A):2669-81. Review. (1 ISI)

Grant WB. Lower vitamin-D production from solar ultraviolet-B irradiance may explain some differences in cancer survivalrates. J Natl Med Assoc. 2006 Mar;98(3):357-64. (9 ISI, 4 GS)

Grant WB. The likely role of vitamin D from solar ultraviolet-B irradiance in increasing cancer survival. Anticancer Res.2006 Jul-Aug;26(4A):2605-14. (12 ISI)

Grant WB. Epidemiology of disease risks in relation to vitamin D insufficiency. Prog Biophys Mol Biol. 2006 Sep;92(1):65-79. (11 ISI, 18 GS)

Grant WB, Garland CF. The association of solar ultraviolet B (UVB) with reducing risk of cancer: multifactorial ecologicanalysis of geographic variation in age-adjusted cancer mortality rates. Anticancer Res. 2006 Jul-Aug;26(4A):2687-99.(46 ISI, 23 GS)

Grant WB, Gorham ED. Commentary: time for public health action on vitamin D for cancer risk reduction. Int J Epidemiol.2006 Apr;35(2):224-5. (5 ISI, 5 GS)

Grimes DS. Are statins analogues of vitamin D? Lancet. 2006 Jul 1;368(9529):83-6. (9 ISI)

Hartge P, Lim U, Freedman DM, Colt JS, Cerhan JR, Cozen W, Severson RK, Davis S. Ultraviolet radiation, dietaryvitamin D, and risk of non-Hodgkin lymphoma (United States). Cancer Causes Control. 2006 Oct;17(8):1045-52. (8 ISI)

Holick MF. Calcium plus vitamin D and the risk of colorectal cancer. N Engl J Med. 2006 May 25;354(21):2287-8; authorreply 2287-8. (3 ISI)

Holick MF. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc. 2006 Mar;81(3):353-73.(39 ISI, 52 GS)

Holick MF. Vitamin D: its role in cancer prevention and treatment. Prog Biophys Mol Biol. 2006 Sep;92(1):49-59. 27 ISI)


20/50

20 | P a g e

Hollender A, Bjoro T, Otto Karlsen K, Kvaloy SO, Nome O, Holte H. Vitamin D deficiency in patients operated on forgastric lymphoma. Scand J Gastroenterol. 2006 Jun;41(6):673-81.

Holt PR, Bresalier RS, Ma CK, Liu KF, Lipkin M, Byrd JC, Yang K. Calcium plus vitamin D alters preneoplastic features ofcolorectal adenomas and rectal mucosa. Cancer. 2006 Jan 15;106(2):287-96.

Houghton LA, Vieth R. The case against ergocalciferol (vitamin D2) as a vitamin supplement. Am J Clin Nutr.2006;84:694-7.

Huang SP, Huang CY, Wu WJ, Pu YS, Chen J, Chen YY, Yu CC, Wu TT, Wang JS, Lee YH, Huang JK, Huang CH, WuMT. Association of vitamin D receptor FokI polymorphism with prostate cancer risk, clinicopathological features andrecurrence of prostate specific antigen after radical prostatectomy. Int J Cancer. 2006 Oct 15;119(8):1902-7.

Johnson CS, Muindi JR, Hershberger PA, Trump DL. The antitumor efficacy of calcitriol: preclinical studies. AnticancerRes. 2006 Jul-Aug;26(4A):2543-9. (3 ISI)

Kemmis CM, Salvador SM, Smith KM, Welsh J. Human mammary epithelial cells express CYP27B1 and are growthinhibited by 25-hydroxyvitamin D-3, the major circulating form of vitamin D-3. J Nutr. 2006 Apr;136(4):887-92. (9 ISI)

Khadzkou K, Buchwald P, Westin G, Dralle H, Akerstrom G, Hellman P. 25-hydroxyvitamin D3 1alpha-hydroxylase andvitamin D receptor expression in papillary thyroid carcinoma. J Histochem Cytochem. 2006 Mar;54(3):355-61.

Klassen AC, Platz EA. What can geography tell us about prostate cancer? Am J Prev Med. 2006 Feb;30(2 Suppl):S7-15.

(2 GS)

Kommagani R, Caserta TM, Kadakia MP. Identification of vitamin D receptor as a target of p63. Oncogene. 2006 Jun22;25(26):3745-51. (6 ISI)

Kong J, Li YC. Molecular mechanism of 1,25-dihydroxyvitamin D3 inhibition of adipogenesis in 3T3-L1 cells. Am J PhysiolEndocrinol Metab. 2006 May;290(5):E916-24.

Koren R, Wacksberg S, Weitsman GE, Ravid A. Calcitriol sensitizes colon cancer cells to H2O2-induced cytotoxicity whileinhibiting caspase activation. J Steroid Biochem Mol Biol. 2006 Oct;101(2-3):151-60.

Krause R, Matulla-Nolte B, Essers M, Brown A, Hopfenmuller W. UV radiation and cancer prevention: what is theevidence? Anticancer Res. 2006 Jul-Aug;26(4A):2723-7. (1 ISI)

Kricker A, Armstrong B. Does sunlight have a beneficial influence on certain cancers? Prog Biophys Mol Biol. 2006Sep;92(1):132-9. (5 ISI)

Lambert JR, Kelly JA, Shim M, Huffer WE, Nordeen SK, Baek SJ, Eling TE, Lucia MS. Prostate derived factor in humanprostate cancer cells: gene induction by vitamin D via a p53-dependent mechanism and inhibition of prostate cancer cellgrowth. J Cell Physiol. 2006 Sep;208(3):566-74. (4 ISI)

Lechner D, Bajna E, Adlercreutz H, Cross HS. Genistein and 17beta-estradiol, but not equol, regulate vitamin D synthesisin human colon and breast cancer cells. Anticancer Res. 2006 Jul-Aug;26(4A):2597-603. (3 ISI)

Lim HS, Roychoudhuri R, Peto J, Schwartz G, Baade P, Moller H. Cancer survival is dependent on season of diagnosisand sunlight exposure. Int J Cancer. 2006;119:1530-36. (12 ISI)

Lipkin M, Lamprecht SA. Mechanisms of action of vitamin D: recent findings and new questions. J Med Food. 2006Summer;9(2):135-7.

Lips P. Vitamin D physiology. Prog Biophys Mol Biol. 2006 Sep;92(1):4-8. (17 GS)

Liu W, Tretiakova M, Kong J, Turkyilmaz M, Li YC, Krausz T. Expression of vitamin D3 receptor in kidney tumors. HumPathol. 2006 Oct;37(10):1268-78.

Lucas RM, Repacholi MH, McMichael AJ. Is the current public health message on UV exposure correct? Bull WorldHealth Organ. 2006 Jun;84(6):485-91. (6 ISI)


21/50

21 | P a g e

Maggi M, Crescioli C, Morelli A, Colli E, Adorini L. Pre-clinical evidence and clinical translation of benign prostatichyperplasia treatment by the vitamin D receptor agonist BXL-628 (Elocalcitol). J Endocrinol Invest. 2006 Jul-

Aug;29(7):665-74. (3 ISI)

Maruyama R, Aoki F, Toyota M, Sasaki Y, Akashi H, Mita H, Suzuki H, Akino K, Ohe-Toyota M, Maruyama Y, Tatsumi H,Imai K, Shinomura Y, Tokino T. Comparative genome analysis identifies the vitamin D receptor gene as a direct target ofp53-mediated transcriptional activation. Cancer Res. 2006 May 1;66(9):4574-83. (6 ISI)

Michaud DS. Vitamin d and pancreatic cancer risk in the alpha-tocopherol, Beta-carotene cancer prevention cohort.Cancer Res. 2006 Oct 15;66(20):9802-3.

Mohr SB, Gorham ED, Garland CF, Grant WB, Garland FC. Are low ultraviolet B and high animal protein intakeassociated with risk of renal cancer? Int J Cancer. 2006 Dec 1;119(11):2705-9.

Moon S, Holley S, Bodiwala D, Luscombe CJ, French ME, Liu S, Saxby MF, Jones PW, Fryer AA, Strange RC.Associations between G/A1229, A/G3944, T/C30875, C/T48200 and C/T65013 genotypes and haplotypes in the vitaminD receptor gene, ultraviolet radiation and susceptibility to prostate cancer. Ann Hum Genet. 2006 Mar;70(Pt 2):226-36.(10 ISI, 5 GS)

Moreno J, Krishnan AV, Peehl DM, Feldman D. Mechanisms of vitamin D-mediated growth inhibition in prostate cancercells: inhibition of the prostaglandin pathway. Anticancer Res. 2006 Jul-Aug;26(4A):2525-30.

Muller K, Schinn M, Reichrath J, Meineke V.1alpha,25-Dihydroxyvitamin D3 modulates the response of humankeratinocytes to ionizing radiation exposure. Anticancer Res. 2006 Jul-Aug;26(4A):2735-41.

Murtaugh MA, Sweeney C, Ma KN, Potter JD, Caan BJ, Wolff RK, Slattery ML. Vitamin d receptor gene polymorphisms,dietary promotion of insulin resistance, and colon and rectal cancer. Nutr Cancer. 2006;55(1):35-43.

Newman LA, Griffith KA, Jatoi I, Simon MS, Crowe JP, Colditz GA. Meta-analysis of survival in African American andwhite American patients with breast cancer: ethnicity compared with socioeconomic status. J Clin Oncol. 2006 Mar20;24(9):1342-9. (14 ISI)

Nonn L, Peng L, Feldman D, Peehl DM. Inhibition of p38 by vitamin D reduces interleukin-6 production in normal prostatecells via mitogen-activated protein kinase phosphatase 5: implications for prostate cancer prevention by vitamin D. CanceRes. 2006 Apr 15;66(8):4516-24. (6 ISI)

Norman AW. Minireview: vitamin D receptor: new assignments for an already busy receptor. Endocrinology. 2006Dec;147(12):5542-8. (10 ISI)

Palmieri C, MacGregor T, Girgis S, Vigushin D. Serum 25-hydroxyvitamin D levels in early and advanced breast cancer. JClin Pathol. 2006 Dec;59(12):1334-6.

Parise RA, Egorin MJ, Kanterewicz B, Taimi M, Petkovich M, Lew AM, Chuang SS, Nichols M, El-Hefnawy T,Hershberger PA. CYP24, the enzyme that catabolizes the antiproliferative agent vitamin D, is increased in lung cancer. IntJ Cancer. 2006 Oct 15;119(8):1819-28.

Pawlik TM, Hawke DH, Liu Y, Krishnamurthy S, Fritsche H, Hunt KK, Kuerer HM. Proteomic analysis of nipple aspiratefluid from women with early-stage breast cancer using isotope-coded affinity tags and tandem mass spectrometry revealsdifferential expression of vitamin D binding protein. BMC Cancer. 2006 Mar 16;6:68. (10 ISI)

Pena C, Garcia JM, Garcia V, Silva J, Dominguez G, Rodriguez R, Maximiano C, Garcia de Herreros A, Munoz A, BonillaF. The expression levels of the transcriptional regulators p300 and CtBP modulate the correlations between SNAIL, ZEB1E-cadherin and vitamin D receptor in human colon carcinomas. Int J Cancer. 2006 Nov 1;119(9):2098-104. (5 ISI)

Peng X, Mehta R, Wang S, Chellappan S, Mehta RG. Prohibitin is a novel target gene of vitamin D involved in itsantiproliferative action in breast cancer cells. Cancer Res. 2006 Jul 15;66(14):7361-9.

Peterlik M, Cross HS. Dysfunction of the vitamin D endocrine system as common cause for multiple malignant and otherchronic diseases. Anticancer Res. 2006 Jul-Aug;26(4A):2581-8. Review.


22/50

22 | P a g e

Plant AS, Tisman G. Frequency of combined deficiencies of vitamin D and holotranscobalamin in cancer patients. NutrCancer. 2006;56(2):143-8.

Polesel J, Talamini R, Montella M, Parpinel M, Dal Maso L, Crispo A, Crovatto M, Spina M, La Vecchia C, Franceschi S.Linoleic acid, vitamin D and other nutrient intakes in the risk of non-Hodgkin lymphoma: an Italian case-control study. AnnOncol. 2006 Apr;17(4):713-8. (8 ISI)

Reichrath J. The challenge resulting from positive and negative effects of sunlight: how much solar UV exposure isappropriate to balance between risks of vitamin D deficiency and skin cancer? Prog Biophys Mol Biol. 2006 Sep;92(1):9-16. (12 ISI, 7 GS)

Saramaki A, Banwell CM, Campbell MJ, Carlberg C. Regulation of the human p21(waf1/cip1) gene promoter via multiplebinding sites for p53 and the vitamin D3 receptor. Nucleic Acids Res. 2006 Jan 24;34(2):543-54. (18 ISI)

Schwartz GG, Hanchette CL. UV, latitude, and spatial trends in prostate cancer mortality: All sunlight is not the same(United States). Cancer Causes Control. 2006 Oct;17(8):1091-101. (6 ISI)

Sepulveda VA, Weigel NL, Falzon M. Prostate cancer cell type-specific involvement of the VDR and RXR in regulation ofthe human PTHrP gene via a negative VDRE. Steroids. 2006 Feb;71(2):102-15.

Shah S, Islam MN, Dakshanamurthy S, Rizvi I, Rao M, Herrell R, Zinser G, Valrance M, Aranda A, Moras D, Norman A,Welsh J, Byers SW. The molecular basis of vitamin D receptor and beta-catenin crossregulation. Mol Cell. 2006 Mar

17;21(6):799-809.

Sieg J, Sieg A, Dreyhaupt J, Schmidt-Gayk H. Insufficient vitamin D supply as a possible co-factor in colorectalcarcinogenesis. Anticancer Res. 2006 Jul-Aug;26(4A):2729-33. (1 ISI)

Skinner HG, Michaud DS, Giovannucci E, Willett WC, Colditz GA, Fuchs CS. Vitamin D intake and the risk of pancreaticcancer in two cohort studies. Cancer Epidemiol Biomarkers Prevention. 2006 Sept,; 15(9):1688-1695. (21 ISI, 8 GS)

Slattery ML, Sweeney C, Murtaugh M, Ma KN, Caan BJ, Potter JD, Wolff R. Associations between vitamin D, vitamin Dreceptor gene and the androgen receptor gene with colon and rectal cancer. Int J Cancer. 2006 Jun 15;118(12):3140-6.(12 ISI)

Spina CS, Tangpricha V, Uskokovic M, Adorinic L, Maehr H, Holick MF. Vitamin D and cancer. Anticancer Res. 2006 Jul-

Aug;26(4A):2515-24. (5 ISI)

Stolzenberg-Solomon RZ, Vieth R, Azad A, Pietinen P, Taylor PR, Virtamo J, Albanes D. A prospective nested case-control study of vitamin d status and pancreatic cancer risk in male smokers. Cancer Res. 2006 Oct 15;66(20):10213-9.(12 ISI, 6 GS)

Sweeney C, Curtin K, Murtaugh MA, Caan BJ, Potter JD, Slattery ML. Haplotype analysis of common vitamin D receptorvariants and colon and rectal cancers. Cancer Epidemiol Biomarkers Prev. 2006 Apr;15(4):744-9. (4 ISI)

Tavani A, Bosetti C, Franceschi S, Talamini R, Negri E, La Vecchia C. Occupational exposure to ultraviolet radiation andrisk of non-Hodgkin lymphoma. Eur J Cancer Prev. 2006 Oct;15(5):453-457.

Tokar EJ, Ancrile BB, Ablin RJ, Webber MM. Cholecalciferol (vitamin D3) and the retinoid N-(4-hydroxyphenyl)retinamide(4-HPR) are synergistic for chemoprevention of prostate cancer. J Exp Ther Oncol. 2006;5(4):323-33.

Trump DL, Potter DM, Muindi J, Brufsky A, Johnson CS. Phase II trial of high-dose, intermittent calcitriol (1,25dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer. Cancer. 2006 May 15;106(10):2136-42. (11 ISI)

Van der Rhee HJ, de Vries E, Coebergh JW. Does sunlight prevent cancer? A systematic review. Eur J Cancer. 2006Sep;42(14):2222-32. (3 ISI, 4 GS)


23/50

23 | P a g e

Veronique-Baudin J, Dieye M, Kouyoumdjian JC, Vacheron F, Draganescu C, Azaloux H. [Case-control study of thegenes of receptors of the androgens of vitamin-D and of 5-alphareductase in a population of Afro-Caribbean populationwith prostate cancer] Prog Urol. 2006 Jun;16(3):303-10. French.

Vieth R, Choo R, Deboer L, Danjoux C, Morton G, Klotz L. Rise in Prostate-Specific Antigen in Men with Untreated Low-Grade Prostate Cancer Is Slower During Spring-Summer. Am J Ther. 2006 September/October;13(5):394-399.

Wactawski-Wende J, Kotchen JM, Anderson GL, Assaf AR, Brunner RL, OSullivan MJ, et al. Calcium plus vitamin Dsupplementation and the risk of colorectal cancer. N Engl J Med 2006;354:68496. (89 ISI, 69 GS)

Walsh J. Calcium and vitamin D. Ch. 31 in Nutritional Oncology, Second Edit., Heber D, Blackburn GL, Go VLW, Milner J(eds.). Academic Press, San Diego, CA. 2006:545-58.

Wolpowitz D, Gilchrest BA. The vitamin D questions: how much do you need and how should you get it? J Am AcadDermatol. 2006 Feb;54(2):301-17. (17 ISI, 24 GS)

Yee SW, Campbell MJ, Simons C. Inhibition of Vitamin D3 metabolism enhances VDR signalling in androgen-independent prostate cancer cells. J Steroid Biochem Mol Biol. 2006 Mar;98(4-5):228-35. (4 ISI)

Yu GP, Hu DN, McCormick SA. Latitude and Incidence of Ocular Melanoma. Photochem Photobiol. 2006;82:1621-6.

Zhang X, Nicosia SV, Bai W. Vitamin D receptor is a novel drug target for ovarian cancer treatment. Curr Cancer DrugTargets. 2006 May;6(3):229-44.

Zhang Y, Zhang J, Studzinski GP. AKT pathway is activated by 1, 25-dihydroxyvitamin D3 and participates in its anti-apoptotic effect and cell cycle control in differentiating HL60 cells. Cell Cycle. 2006 Feb;5(4):447-51. (6 ISI)

Zhou W, Heist RS, Liu G, Neuberg DS, Asomaning K, Su L, Wain JC, Lynch TJ, Giovannucci E, Christiani DC.Polymorphisms of vitamin d receptor and survival in early-stage non-small cell lung cancer patients. Cancer EpidemiolBiomarkers Prev. 2006 Nov;15(11):2239-45.

2005(6+ citat) (73 papers, 31>13)

Adachi R, Honma Y, Masuno H, Kawana K, Shimomura I, Yamada S, Makishima M. Selective activation of vitamin Dreceptor by lithocholic acid acetate, a bile acid derivative. J Lipid Res. 2005 Jan;46(1):46-57. (16 ISI)

Baquet CR, Commiskey P, Mack K, Meltzer S, Mishra SI. Esophageal cancer epidemiology in blacks and whites: racialand gender disparities in incidence, mortality, survival rates and histology. J Natl Med Assoc. 2005 Nov;97(11):1471-8.

Baron JA, Beach M, Wallace K, Grau MV, Sandler RS, Mandel JS, Heber D, Greenberg ER. Risk of prostate cancer in arandomized clinical trial of calcium supplementation. Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):586-9. (14 ISI)

Beer TM, Myrthue A, Eilers KM. Rationale for the development and current status of calcitriol in androgen-independentprostate cancer. World J Urol. 2005 Feb;23(1):28-32. (9 ISI, 5 GS)

Bernstein H, Bernstein C, Payne CM, Dvorakova K, Garewal H. Bile acids as carcinogens in human gastrointestinalcancers. Mutat Res. 2005 Jan;589(1):47-65. (21 ISI)

Bertone-Johnson ER, Chen WY, Holick MF, Hollis BW, Colditz GA, Willett WC, Hankinson SE. Plasma 25-hydroxyvitaminD and 1,25-dihydroxyvitamin D and risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):1991-7. (22ISI, 20 GS)

Berube S, Diorio C, Masse B, Hebert-Croteau N, Byrne C, Cote G, Pollak M, Yaffe M, Brisson J. Vitamin D and calciumintakes from food or supplements and mammographic breast density. Cancer Epidemiol Biomarkers Prev. 2005Jul;14(7):1653-9. (13 ISI, 7 GS)


24/50

24 | P a g e

Berwick M, Armstrong BK, Ben-Porat L, Fine J, Kricker A, Eberle C, Barnhill R. Sun exposure and mortality frommelanoma. J Natl Cancer Inst. 2005 Feb 2;97(3):195-9. (36 ISI, 92 GS)

Berwick M, Kesler D. Ultraviolet radiation exposure, vitamin D, and cancer. Photochem Photobiol. 2005 Nov-Dec;81(6):1261-6. Review.

Chang ET, Blomqvist P, Lambe M. Seasonal variation in the diagnosis of Hodgkin lymphoma in Sweden. Int J Cancer.2005 May 20;115(1):127-30.

Chen WY, Bertone-Johnson ER, Hunter DJ, Willett WC, Hankinson SE. Associations between polymorphisms in thevitamin D receptor and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2335-9. (15 ISI)

Crescioli C, Morelli A, Adorini L, Ferruzzi P, Luconi M, Vannelli GB, Marini M, Gelmini S, Fibbi B, Donati S, Villari D, FortiG, Colli E, Andersson KE, Maggi M. Human bladder as a novel target for vitamin D receptor ligands. J Clin EndocrinolMetab. 2005 Feb;90(2):962-72. (13 ISI)

Cross HS, Bises G, Lechner D, Manhardt T, Kallay E. The Vitamin D endocrine system of the gut--its possible role incolorectal cancer prevention. J Steroid Biochem Mol Biol. 2005 Oct;97(1-2):121-8. (16 ISI)

Dixon KM, Deo SS, Wong G, Slater M, Norman AW, Bishop JE, Posner GH, Ishizuka S, Halliday GM, Reeve VE, MasonRS. Skin cancer prevention: a possible role of 1,25dihydroxyvitamin D3 and its analogs. J Steroid Biochem Mol Biol. 2005Oct;97(1-2):137-43. (19 ISI)

Dunlop TW, Vaisanen S, Frank C, Molnar F, Sinkkonen L, Carlberg C. The human peroxisome proliferator-activatedreceptor delta gene is a primary target of 1alpha,25-dihydroxyvitamin D3 and its nuclear receptor. J Mol Biol. 2005 Jun3;349(2):248-60. (8 ISI)

Egan KM, Sosman JA, Blot WJ. Sunlight and reduced risk of cancer: is the real story vitamin D? J Natl Cancer Inst. 2005Feb 2;97(3):161-3. (23 ISI, 40 GS)

Flood A, Peters U, Chatterjee N, Lacey JV Jr, Schairer C, Schatzkin A. Calcium from diet and supplements is associatedwith reduced risk of colorectal cancer in a prospective cohort of women. Cancer Epidemiol Biomarkers Prev. 2005Jan;14(1):126-32. (8 ISI)

Gilad LA, Bresler T, Gnainsky J, Smirnoff P, Schwartz B. Regulation of vitamin D receptor expression via estrogen-induced activation of the ERK 1/2 signaling pathway in colon and breast cancer cells. J Endocrinol. 2005 Jun;185(3):577-

92. (10 ISI, 1 GS)

Giovannucci E. The epidemiology of vitamin D and cancer incidence and mortality: a review (United States). CancerCauses Control. 2005 Mar;16(2):83-95. Review. (77 ISI, 81 GS)

Gombart AF, Borregaard N, Koeffler HP. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of thevitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. FASEB J. 2005Jul;19(9):1067-77. (24 ISI)

Gorham ED, Garland CF, Garland FC, Grant WB, Mohr SB, Lipkin M, Newmark HL, Giovannucci E, Wei M, Holick MF.Vitamin D and prevention of colorectal cancer. J Steroid Biochem Mol Biol. 2005 Oct;97(1-2):179-94. (48 ISI, 43 GS)

Grant WB, Garland CF, Holick, MF. Comparisons of estimated economic burdens due to insufficient solar ultravioletirradiance and vitamin D and excess solar UV irradiance for the United States. Photochem Photobiol. 2005;81:1276-86.(25 ISI, 17 GS)

Grant WB, Holick MF. Benefits and requirements of vitamin D for optimal health: a review. Altern Med Rev. 2005;10:94-111. (59 ISI, 45 GS)

Gross MD. Vitamin D and calcium in the prevention of prostate and colon cancer: new approaches for the identification ofneeds. J Nutr. 2005 Feb;135(2):326-31. Review. (16 ISI, 8 GS)


25/50

25 | P a g e

Hartman TJ, Albert PS, Snyder K, Slattery ML, Caan B, Paskett E, Iber F, Kikendall JW, Marshall J, Shike M, Weissfeld J,Brewer B, Schatzkin A, Lanza E; Polyp Prevention Study Group. The association of calcium and vitamin D with risk ofcolorectal adenomas. J Nutr. 2005 Feb;135(2):252-9. (15 ISI)

Hayes VM, Severi G, Padilla EJ, Eggleton SA, Southey MC, Sutherland RL, Hopper JL, Giles GG. Genetic variants in thevitamin D receptor gene and prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 2005 Apr;1

Documents

Vitamin D cancer studies